Resources

A computerized, self-administered test of verbal episodic memory in elderly patients with mild cognitive impairment and healthy participants: A randomized, crossover, validation study

by Sydney Araya | November 19, 2018 | Publications and Articles

A computerized, self-administered test of verbal episodic memory in elderly patients with mild cognitive impairment and healthy participants: A randomized, crossover, validation study Randall L. Morrison, Huiling Pei, Gerald Novak, Daniel I. Kaufer, Kathleen A. Welsh-Bohmer, Stephen Ruhmel, Vaibhav A. Narayan Abstract: Introduction: Performance of “Revere”, a novel iPad-administered word-list recall (WLR) test, in quantifying […]

Read More

A Multicenter, Randomized, Active-Control Registration Trial (STARS-ADHD) to Assess the Efficacy and Safety of a Novel, Home-Based, Digital Treatment for Pediatric Attention-Deficit Hyperactivity Disorder

by Sydney Araya | November 12, 2018 | Posters

Presented at AACAP Annual Meeting, Seattle, WA, USA, October 22-27, 2018 A MULTICENTER, RANDOMIZED, ACTIVE-CONTROL REGISTRATION TRIAL(STARS-ADHD) TO ASSESS THE EFFICACY AND SAFETY OF A NOVEL, HOME-BASED, DIGITAL TREATMENT FOR PEDIATRIC ATTENTION-DEFICIT HYPERACTIVITY DISORDER S.H. Kollins,1 J. Bower,2 R.L. Findling,3 R. Keefe,1,4 J.N. Epstein,5 A.J. Cutler,6 R. White,7 L. Aberle,7 D. DeLoss,2 S.V. Faraone8 31249 […]

Read More

A Multicenter, Randomized, Active-Control Registration Trial (STARS-ADHD) to Assess the Efficacy and Safety of a Novel, Home-Based, Digital Treatment for Pediatric ADHD

by Sydney Araya | November 12, 2018 | Posters

Presented at the CHADD 2018 Annual International Conference on ADHD, November 8-11, 2018 in St. Louis, Missouri A MULTICENTER, RANDOMIZED, ACTIVE-CONTROL REGISTRATION TRIAL (STARS-ADHD) TO ASSESS THE EFFICACY AND SAFETY OF A NOVEL, HOME-BASED, DIGITAL TREATMENT FOR PEDIATRIC ADHD S.H. Kollins,1 J. Bower,2 T. Ala’ilima,2 R.L. Findling,3 R Keefe,1,4 J.N. Epstein,5 A.J. Cutler,6 R. White,7 L. Aberle,7 […]

Read More

Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency)

by Sydney Araya | November 5, 2018 | Publications and Articles

If you were at all connected to the popular media in the early part of this decade, you may recall seeing regular advertisements about the computerized brain training product Lumosity. The claims made in those ads boiled the blood of many clinical researchers and neuroscientists who were engaged in painstakingly testing the efficacy of various […]

Read More

Predictive value and test-retest reliability of the tablet-based Brief Assessment of Cognition (BAC App) for assessment of cognition in aging: preliminary findings from an ongoing normative study

by Sydney Araya | October 30, 2018 | Posters

Presented at CTAD and CNS Summit 2018 VeraSci presented results of a recent study utilizing is a brief tablet-based assessment of the paper-and-pencil based Brief Assessment of Cognition (BACS) assessing multiple cognitive domains, including verbal memory, working memory, motor function, verbal fluency, processing speed and executive function. We presented results examining criterion validity for the […]

Read More

Assessing decline in visuospatial working memory associated with subjective cognitive impairment using a tablet-based measure of hippocampal-dependent learning

by Sydney Araya | October 30, 2018 | Posters

Presented at CTAD 2018 Poster 74 “Assessing decline in visuospatial working memory associated with subjective cognitive impairment using a tablet-based measure of hippocampal-dependent learning” Authors: Alexandra S. Atkins, Anzalee Khan, Daniel Ulshen, John Harrison, Brenda L. Plassman,Kathleen A. Welsh-Bohmer & Richard S.E. Keefe VeraSci presented results of a recent study utilizing a novel tablet-based visuospatial […]

Read More

Evaluation of Relationship Between Negative Symptoms Scales in an IRT Framework

by Ashley Davis | October 30, 2018 | Posters

Anzalee Khan, PhD, Senior Director of Data Science at VeraSci, presented “Evaluation of Relationship Between Negative Symptoms Scales in an IRT Framework.” at ISCTM’s 2018 autumn conference. There are many assessments of negative symptoms in schizophrenia with no clear consensus on the primary scale to use for this population as the constructs and general utility of each scale varies. This […]

Read More

Common Rater Errors for Assessment in Pediatric Rare and Orphan Disease Trials

by Ashley Davis | October 30, 2018 | Posters

Carmen E. Sanchez, PhD, Senior Director of R&O at VeraSci presented “Common Rater Errors for Assessment in Pediatric Rare and Orphan Disease Trials.” at ISCTM’s 2018 autumn conference. The presentation investigated the impact of data quality review, by quantifying the number of scoring and administration errors typically found in a paper-based review of cognitive and […]

Read More

TOMMORROW neuropsychological battery: German language validation and normative study

by Ashley Davis | October 19, 2018 | Publications and Articles

Read More

ISCTM 14th Annual Scientific Meeting

by James Riley | February 20, 2018 | Posters

Read More

Pioneering Prodromal Science – The Evolution of Prediction & Prevention in Psychotic Disorders

by Rich Keefe, PhD. | November 29, 2017 | Publications and Articles

by Rich Keefe, Ph.D. When physicians interviewed patients hospitalized after their initial psychotic episode, they were startled to learn that in many cases, “people began experiencing changes in cognition, behavior, and perception for months or years before psychosis struck,” says Dr. Robert Heinssen of the National Institute of Mental Health in the recent Science article, A […]

Read More

CNS Summit Recap: Where Clinical Trials, Life Sciences, and Technology Meet

by James Riley | November 21, 2017 | Posters

As CNS Summit came to an end, we left inspired to continue the conversation on emerging industry trends, disruptive technology, and global regulations.  From addressing the future of digital biomarkers and wearables to the regulatory implications of international data capture, NeuroCog Trials was thrilled to participate in a conference focused on what matters most, enabling […]

Read More

NCT Linguistics’ Parent Company, NeuroCog Trials, Announces the Addition of Dr. Luca Pani – Press Release

by Brittany Pelegrino | September 18, 2017 | Publications and Articles

DURHAM, NORTH CAROLINA, September 18, 2017 NeuroCog Trials (NCT), a clinical technology and research services company dedicated to supporting global drug development, announces the addition of former AIFA Director General, Dr. Luca Pani, as Executive Director of Global Medical Innovation. Dr. Pani will guide the company’s development of innovative solutions for clinical trials methodologies and […]

Read More

Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction

by James Riley | July 27, 2017 | Publications and Articles

Individuals at clinical high risk (CHR) often present with a mixture of dif culties in addition to subthreshold psychotic symptoms, such as neurocognitive decline, premorbid dysfunction, and anxious/mood disorders.1–4 Heterogeneity impedes research by obscuring potentially discrete subtypes, which hinders clinical research, evalua- tion, and treatment.

Read More

NEUROCOG TRIALS INTRODUCES NCT PATHWAY: NEXT GENERATION eCOA FOR CLINICAL TRIALS – PRESS RELEASE

by Brittany Scaturro | July 13, 2017 | Publications and Articles

Innovative platform designed to deliver the highest quality of clinical data, streamline site processes, and improve patient experience   DURHAM, NORTH CAROLINA, JULY 13, 2017 – NeuroCog Trials (NCT), a clinical technology and research services company dedicated to supporting global drug development, announces the general availability of its new flagship eCOA platform, NCT Pathway. Developed […]

Read More

Placebo Response and Practice Effects in Schizophrenia Cognition Trials

by Brittany Scaturro | July 11, 2017 | Publications and Articles

Questions:  What is the magnitude of learning effects in patients with schizophrenia receiving placebo on the criterion standard Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB), and can these learning effects be anticipated in individual patients?

Read More

Cognitive burden of anticholinergic medications in psychotic disorders

by Brittany Scaturro | April 13, 2017 | Publications and Articles

Patients with psychotic disorders are often treated with numerous medications, many of which have anticholinergic activity. We assessed cognition in relation to the cumulative anticholinergic burden of multiple drugs included in treatment regimens of participants from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.

Read More

Development and Validation of the Tablet-based Brief Assessment of Cognition (BAC App) for Schizophrenia

by Brittany Scaturro | April 5, 2017 | Posters

This poster was presented at the International Congress on Schizophrenia Research in San Diego 24-28 March 2017. The Brief Assessment of Cognition in Schizophrenia (BACS) is a pen-and-paper cognitive assessment tool that has been used in hundreds of research studies and clinical trials, and has normative data available for generating age- and gender-corrected standardized scores. A […]

Read More

Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia

by Brittany Scaturro | March 28, 2017 | Publications and Articles

Article in JAMA Psychiatry One of the greatest challenges for the identification of the causes and cures for schizophrenia is the overwhelming heterogeneity of the disorder. Schizophrenia is defined by symptoms that have only weak associations with one another and are found in patients with other illnesses. Further, some of the most devastating symptoms, such […]

Read More

Validation of the Tablet-based Brief Assessment of Cognition (BAC App) for Schizophrenia

by Brittany Scaturro | March 17, 2017 | Posters

This poster was Presented at the Annual Meeting of the American Society for Experimental NeuroTherapeutics (ASENT)  15-17 March 2017 Washington DC/Rockville MD Computerized tests benefit from automated scoring procedures and standardized administrator instructions. These methods can reduce the potential for rater error.

Read More

Assessing Functional Capacity using the UCSD Performance-based Skills Assessment (UPSA-2-VIM) and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)

by Brittany Scaturro | March 17, 2017 | Posters

This poster was presented at the Annual Meeting of the American Society for Experimental NeuroTherapeutics (ASENT)  15-17 March 2017 Washington DC/Rockville MD Reliable measurement of functional capacity is critical in assessing the efficacy of treatments for cognitive impairment in a wide range of CNS disorders including

Read More

Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia

by Brittany Scaturro | February 28, 2017 | Publications and Articles

The Schizophrenia Cognition Rating Scale (SCoRS) is an interview-based assessment of cognition that involves interviews with patients and informants. The SCoRS has shown good reliability, validity, and sensitivity to cognitive impairment in schizophrenia, with the advantage of brief administration and scoring time. The present study aimed to test the concurrent validity of the Persian version […]

Read More

Innovative Technologies Expedite Cognition Drug Development – Article

by Brittany Scaturro | January 3, 2017 | Publications and Articles

NeuroCog Trials develops innovative technologies that use virtual reality and computerized assessments to augment the measurement of cognitive and functional abilities in clinical trials. Both the VRFCAT – Virtual Reality Functional Capacity Assessment Tool and BAC App – Brief Assessment of Cognition App were recently highlighted in the Research Features Magazine. Find a link to […]

Read More

Cultural Adaptation of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) for Use in the UK and Canada

by Brittany Scaturro | November 1, 2016 | Posters

The poster contains a discussion of methods for cross-cultural adaptation of performance-based outcome assessments:

Read More

Validation of the tablet-administered Brief Assessment of Cognition (BAC App)

by Brittany Scaturro | November 1, 2016 | Publications and Articles

The validation study of our proprietary Brief Assessment of Cognition (BAC App) is now in press in Schizophrenia Research, available as Open Access PDF.

Read More

Rasch Analysis to Test the Cross-Cultural Item Equivalence of the Alzheimer’s Disease Assessment Scale – Cognitive (ADAS-Cog)

by Brittany Scaturro | October 11, 2016 | Posters

Poster: Rasch Analysis to Test the Cross-Cultural Item Equivalence of the Alzheimer’s Disease Assessment Scale – Cognitive (ADAS-Cog)

Read More

IOM Neuroscience Trials of the Future (Second Update)

by Brittany Scaturro | September 8, 2016 | Publications and Articles

UPDATE SEPTEMBER 8, 2016: The prepublication of  Neuroscience Trials of the Future: Proceedings of a Workshop is now available online at the National Academies Press. UPDATE APRIL 5, 2016: Presentations are now available for review at Neuroscience Trials of the Future: A Workshop (Click on Presentations at top right) Institute of Medicine (IOM), Washington, DC, 3-4th […]

Read More

NeuroCog Trials Receives $2 Million Grant from the National Institute of Mental Health – Press Release

by Brittany Scaturro | August 11, 2016 | Publications and Articles

NIH Grant Will Support the Collection of US Census-Matched Norms and Internationalization of the Virtual Reality Functional Capacity Assessment Tool, VRFCAT™.   DURHAM, NORTH CAROLINA, August 11, 2016 – NeuroCog Trials, Inc., the leading cognitive services provider for the clinical trials industry, today announced that it has been awarded a Phase IIB grant from the […]

Read More

Assessing the Impact of Centralized Data Review on the Reliability of the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog)

by Brittany Scaturro | August 4, 2016 | Posters

The Alzheimer’s Disease Assessment Scale Cognitive Subscale (ADAS-Cog) is the primary neurocognitive outcome measure in many clinical trials for mild-moderate Alzheimer’s disease (AD). Despite wide use, variations in administration and scoring are well-documented, and may reduce reliability and sensitivity of the measure. Variations in administration practices, misinterpretation of scoring rules, and intra-rater drift are among […]

Read More

Implementing Neurocognitive Testing in Clinical Trials: Facilitating Rater Administration with an iPad-based App

by Brittany Scaturro | July 5, 2016 | Publications and Articles

To facilitate rater administration of neurocognitive testing in clinical trials, we developed an iPad-based application (BAC App) of a widely used pen-and-paper battery, the Brief Assessment of Cognition (BAC). The purpose of the BAC App is to reduce administration burden on site raters by automating and standardizing the testing procedures and scoring, while maintaining the […]

Read More

NeuroCog Trials Receives $1.4MM Grant From The National Institute On Aging

by Brittany Scaturro | May 19, 2016 | Publications and Articles

NIH Funding Will Support Further Development Of The BAC App For Use As A Screening Tool For Cognitive Decline In Aging Populations   DURHAM, NORTH CAROLINA, May 18, 2016 – NeuroCog Trials, Inc., the leading cognitive services provider for the clinical trials industry, today announced that it has been awarded a 2016 Direct to Phase II […]

Read More

Validation of The Virtual Reality Functional Capacity Assessment Tool (VRFCAT) is published

by Brittany Scaturro | May 5, 2016 | Publications and Articles

The validation study of NeuroCog Trials’ Virtual Reality Functional Capacity Assessment Tool (VRFCAT) is now in press in Schizophrenia Research, available as Open Access. Performance on the VRFCAT was compared to the MATRICS Consensus Cognitive Battery (MCCB) and the UCSD Performance-based Skills Assessment (UPSA) in 167 patients with schizophrenia, and 166 healthy controls, at 3 […]

Read More

The BACS and near-infrared spectroscopy (NIRS) as a biomarker in schizophrenia drug trials

by Brittany Scaturro | February 22, 2016 | Publications and Articles

A new study published in Schizophrenia Research used the Brief Assessment of Cognition in Schizophrenia (BACS) to investigate the correlation between cognitive function and brain activity in the frontal and temporal lobes, measured with NIRS during a memory task. The study was conducted at Tottori University Hospital in Japan, using the Japanese language version of […]

Read More

Validation of the Tablet-based Brief Assessment of Cognition (BAC App) for Schizophrenia

by Brittany Scaturro | February 19, 2016 | Posters

The Brief Assessment of Cognition in Schizophrenia (BACS) is a pen-and-paper cognitive assessment tool that has been used in hundreds of research studies and clinical trials, and has normative data available for generating age-and gender-corrected standardized scores. A tablet-based version of the BACS called the BAC App has been developed.

Read More

How do key co-primary measures of functional capacity predict real world function in schizophrenia?

by Brittany Scaturro | February 19, 2016 | Posters

Research suggests that cognitive impairment in schizophrenia accounts for more disability in real world functioning than any other aspect of the illness, including psychosis (e.g. August, 2012).

Read More

Examining effects of language and region on test-retest reliability of the MATRICS Consensus Cognitive Battery (MCCB)

by Brittany Scaturro | February 19, 2016 | Posters

The MATRICS Consensus Cognitive Battery (MCCB) is the primary cognitive test battery recommended for clinical trials in schizophrenia populations. The MCCB has been successfully translated to multiple foreign languages and used in many international clinical trials, which has generated an interest to test whether language and regional differences have an influence on the psychometric characteristics […]

Read More

The genetic association of synaptic protein variants with cognition in schizophrenia, using the BACS

by Brittany Scaturro | February 16, 2016 | Publications and Articles

The study of 342 patients with schizophrenia showed significant effects of the adducin ADD2 polymorphisms, with CC genotype carriers performing better on almost all cognitive domains assessed by the Brief Assessment of Cognition in Schizophrenia (BACS).

Read More

NeuroCog Trials launches language division for complex translations

by Brittany Scaturro | January 19, 2016 | Publications and Articles

      PRESS RELEASE Durham, January 19, 2016– NeuroCog Trials is excited to announce a new division, NCT Linguistics, a language service provider focused on the life sciences industry and the global need for precision translations.

Read More

Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia

by Brittany Scaturro | January 8, 2016 | Publications and Articles

If treatments for cognitive impairment are to be utilized successfully, clinicians must be able to determine whether they are effective and which patients should receive them.

Read More

Cognitive Impairment in Schizophrenia and Poor Functional Outcomes: Understanding the Research and Patients’ Real-World Experiences

by Brittany Scaturro | January 5, 2016 | Publications and Articles

Developed in conjunction with a panel of experts in the field of schizophrenia, this eBook aims to provide an overview of a core, yet often overlooked, feature of schizophrenia: cognitive impairment. Cognitive impairment in schizophrenia is associated with poor functional outcomes. To help you better understand this condition, the expert clinicians featured in the eBook […]

Read More

NIMH study uses the Brief Assessment of Cognition with NeuroCog Trials support to find that cognitive outcomes are stronger than diagnosis in parsing psychosis subgroups

by Brittany Scaturro | December 9, 2015 | Publications and Articles

A new NIMH-funded study shows that biological factors better classify psychosis than observable symptoms. This supports NIMH’s Research Diagnostic Criteria (RDoC) initiative, which frees scientists from designing research based on traditional diagnostic categories,

Read More

Circumstances under which practice does not make perfect: A review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies

by Brittany Scaturro | November 18, 2015 | Publications and Articles

In this article, we review the literature on practice effects in schizophrenia, an underappreciated confound in interpreting cognitive improvement in clinical trials. We first examine claims regarding first- and second-generation antipsychotic medications as cognitive enhancers, and follow it with a discussion of recent studies demonstrating how practice or placebo effects may drive ‘positive’ findings. Thus, […]

Read More

Impact of Expert Data Review and Centralized Scoring on Test-Retest Reliability of the ADAS-Cog

by Brittany Scaturro | November 6, 2015 | Posters

CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) BARCELONA, SPAIN, NOVEMBER 5-7, 2015 Clinical trials devote considerable effort and resources to rater training and quality assurance of ADAS-Cog endpoints. To examine the efficacy of these efforts in improving ADAS­Cog reliability, we evaluated the impact of central data review on ADAS­-Cog test-­retest reliability. Results indicate that central data […]

Read More

Cultural Adaptation of the TOMMORROW Cognitive Battery in Russia, Switzerland, and Italy

by Brittany Scaturro | November 6, 2015 | Posters

CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) BARCELONA, SPAIN, NOVEMBER 5-7, 2015 Cultural adaptation of cognitive assessments improves the quality of translated instruments by ensuring tasks, stimuli, and instructions are understood and are

Read More

Normative Study of the German Language TOMMORROW Neuropsychological Battery

by Brittany Scaturro | November 6, 2015 | Posters

CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) BARCELONA, SPAIN, NOVEMBER 5-7, 2015 The TOMMORROW Study is an international trial using MCI-AD as the primary endpoint. In preparation for initiating the TOMMORROW Study in German-speaking countries, we conducted a validation and normative study of the TOMMORROW neurocognitive battery in Basel, Switzerland. View poster  

Read More

Normative Study of the Italian Language TOMMORROW Neurocognitive Battery

by Brittany Scaturro | November 6, 2015 | Posters

CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) BARCELONA, SPAIN, NOVEMBER 5-7, 2015 The TOMMORROW Study is an international trial using MCI-AD as the primary endpoint. In order to facilitate assessment of participants in Italy, we conducted a validation and normative study of the TOMMORROW neurocognitive battery in Rome and Brescia, Italy. View poster

Read More

Normative Study of the Russian TOMMORROW Neuropsychological Battery

by Brittany Scaturro | November 6, 2015 | Posters

  CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) BARCELONA, SPAIN, NOVEMBER 5-7, 2015 The TOMMORROW Study is an international trial using MCI-AD as the primary endpoint. In order to facilitate assessment of participants in Russia,we conducted a validation and normative study of the TOMMORROW neuropsychological battery in Tomsk, Russia. View poster

Read More

Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia)

by Brittany Scaturro | November 5, 2015 | Publications and Articles

The Brief Assessment of Cognition in Schizophrenia was administered to 116 stable patients with schizophrenia and 58 matched control subjects. To assess concurrent validity, a subset of patients underwent a traditional neuropsychological assessment. Araujo GE, Resende CB, Cardoso AC, Teixeira AL, Keefe RS, Salgado JV. Validity and reliability of the Brazilian Portuguese version of the […]

Read More

Lifetime comorbidity, lifetime history of psychosis and suicide attempts, and current symptoms of patients with deteriorated affective disorder

by Brittany Scaturro | November 2, 2015 | Publications and Articles

This study extends our prior research by examining the lifetime comorbidity, history of psychosis and suicide attempts, and current symptoms of an unusual group of patients with major affective disorders who have not only been symptomatic for prolonged periods but have also been so functionally impaired that they required years of care in psychiatric facilities […]

Read More

Examining Placebo Effects on MATRICS Battery Measures in Schizophrenia Cognition Clinical Trials

by Brittany Scaturro | October 12, 2015 | Posters

CNS Summit Boca Raton, Florida 8-11 October 2015 The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Battery (MCCB) is described as the “gold standard” by members of the Psychiatry Division of the US FDA and the European Medicines Agency. The psychometrics of the MCCB have been increasingly well established. However, the […]

Read More

The Tablet-based Brief Assessment of Cognition (BAC App) for Schizophrenia

by Brittany Scaturro | October 12, 2015 | Posters

CNS Summit Boca Raton, FL 8-11 October 2015 The Brief Assessment of Cognition in Schizophrenia (BACS) is a pen-and-paper cognitive assessment tool that has been used in hundreds of research studies and clinical trials, and has normative data available for generating age- and gender-corrected standardized scores. A tablet-based version of the BACS called the BAC […]

Read More

Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first episode schizophrenia.

by Brittany Scaturro | October 5, 2015 | Publications and Articles

Deficient vitamin D levels are very common among Americans of all ages and ethnicities, but little is known about its prevalence or associated problems among those with schizophrenia. Early Interv Psychiatry. 2015 Oct;9(5):397-405. doi: 10.1111/eip.12122. Epub 2014 Feb 24.  

Read More

Assessment of age-related differences in functional capacity using the Virtual Reality Functional Assessment Tool (VRFCAT)

by Brittany Scaturro | October 5, 2015 | Publications and Articles

Clinical trials for primary prevention and early intervention in preclinical AD require measures of functional capacity with improved sensitivity to deficits in healthier, non-demented individuals. To this end, the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) was developed as a direct performance-based assessment of functional capacity that is sensitive to changes in function across multiple […]

Read More

Cognitive Disturbances in Major Depression: What Are We Missing?

by Pierre Roux | September 24, 2015 | Publications and Articles

Dr. Keefe recently presented new major findings on major depression. Follow the link below and follow the instructions at the bottom of each page to view the video. View Full Article

Read More

Latent structure of cognition in schizophrenia: A confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB)

by Brittany Scaturro | September 5, 2015 | Publications and Articles

The number of separable cognitive dimensions in schizophrenia has been debated. Guided by the extant factor analytic literature, the NIMH Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative selected seven cognitive domains relevant to treatment studies in schizophrenia: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, […]

Read More

Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extended beyond deficits predicted by generalized neuropsychological impairment

by Brittany Scaturro | August 5, 2015 | Publications and Articles

Working memory impairment is well established in psychotic disorders. However, the relative magnitude, diagnostic specificity, familiality pattern, and degree of independence from generalized cognitive deficits across psychotic disorders remain unclear. Hill KS, Buchholz A, Amsbaugh H, Reilly JL, Rubin LH, Gold JM, Keefe RS, Pearlson GD, Keshavan MS, Tamminga CA, Sweeney JA. Working memory impairment […]

Read More

Impact of Expert Data Review and Centralized Scoring on Test-Retest Reliability of the ADAS-Cog

by Brittany Scaturro | July 18, 2015 | Posters

AAIC 2015 Washington, DC, July 18-23 2015 The Alzheimer’s Disease Assessment Scale Cognitive Subscale (ADAS-Cog) is the primary neurocognitive outcome measure in many clinical trials for mild-moderate Alzheimer’s disease (AD). Despite wide use, variations in administration and scoring are well-documented (1), and may reduce reliability and sensitivity of the measure (2). Clinical trials devote considerable […]

Read More

A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder.

by Brittany Scaturro | July 5, 2015 | Publications and Articles

This multicenter, randomized, double-blind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of vortioxetine (10-20 mg) on cognitive function in adults (aged 18-65 years) diagnosed with major depressive disorder (MDD) who self-reported cognitive dysfunction. Efficacy was evaluated using ANCOVA for the change from baseline to week 8 in the digit […]

Read More

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

by Brittany Scaturro | June 19, 2015 | Publications and Articles

Encenicline is a novel, selective α7 nicotinic acetylcholine receptor agonist in development for treating cognitive impairment in schizophrenia and Alzheimer’s disease. A phase 2, double-blind, randomized, placebo-controlled, parallel-design, multinational study was conducted. Patients with schizophrenia on chronic stable atypical antipsychotics were randomized to encenicline 0.27 or 0.9 mg once daily or placebo for 12 weeks. The […]

Read More

Longitudinal Analysis of the Individual Placebo Response from Double-blind Clinical Studies using the MATRICS Consensus Cognitive Battery (MCCB) in Cognitive Impairment Associated with Schizophrenia (CIAS)

by Brittany Scaturro | June 17, 2015 | Posters

The MATRICS Consensus Cognitive Battery (MCCB) was developed to provide an assessment of cognitive impairment and measure change in clinical trials for Cognitive Impairment Associated with Schizophrenia (CIAS). While pivotal trials are expected to be 24 weeks in duration to characterize the benefit risk of an investigational product to treat (CIAS), earlier clinical studies such […]

Read More

Effects of glutamate positive modulators on cognitive deficts in schizophrenia: A systematic review and meta-analysis of double-blind randomized controlled trials

by Brittany Scaturro | June 16, 2015 | Publications and Articles

Hypofunction of N-methyl-d-aspartate (NMDA) receptors has been proposed to have an important role in the cognitive impairments observed in schizophrenia. Although glutamate modulators may be effective in reversing such difficult-to-treat conditions, the results of individual studies thus far have been inconsistent. We conducted a systematic review and meta-analysis to examine whether glutamate positive modulators have […]

Read More

Phase 2 trial of an Alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia

by Brittany Scaturro | June 12, 2015 | Publications and Articles

This trial was conducted to test the effects of an alpha7 nicotinic receptor full agonist, TC-5619, on negative and cognitive symptoms in subjects with schizophrenia. Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC. Phase 2 trial of an Alpha-7 […]

Read More

Magnitude and Predictors of MATRICS Consensus Cognitive Battery Change in Placebo Treated Patients with Schizophrenia

by Brittany Scaturro | May 14, 2015 | Presentation

Society of Biological Psychiatry’s 70th Annual Meeting Toronto, May 14-16 2015 View Poster

Read More

A phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

by Brittany Scaturro | May 5, 2015 | Publications and Articles

This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H₃ receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7 weeks (4 weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite […]

Read More

Validation of a computerized assessment of functional capacity

by Brittany Scaturro | March 28, 2015 | Presentation

15th International Congress on Schizophrenia Research Colorado Spring, March 28-April 1 2015 View Poster

Read More

Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: a diffusion tensor imaging study

by Brittany Scaturro | March 5, 2015 | Publications and Articles

Clinical evidence shows that bipolar disorder (BD) is characterized by white matter (WM) microstructural abnormalities. However, little is known about the biological mechanisms associated with these abnormalities and their relationship with cognitive functioning. Bauer IE, Ouyang A, Mwangi B, Sanches M, Zunta-Soares GB, Keefe RSE, Huang H, Soares JC. Reduced white matter integrity and verbal […]

Read More

Observable Social Cognition: A Rating Scale (OSCARS): An interview-based assessment for schizophrenia

by Brittany Scaturro | February 13, 2015 | Publications and Articles

Individuals with schizophrenia consistently show impairments in social cognition (SC). SC has become a potential treatment target due to its association with functional outcomes. An alternative method of assessment is to administer an observer-based scale incorporating an informant’s “first hand” impressions in ratings. Healey K, Combs D, Gibson C, Keefe R, Roberts D, Penn D. […]

Read More

Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale

by Brittany Scaturro | February 8, 2015 | Publications and Articles

Cognitive functioning can be assessed with performance-based assessments such as neuropsychological tests and with interview-based assessments. Both assessment methods have the potential to assess whether treatments for schizophrenia improve clinically relevant aspects of cognitive impairment. Keefe RSE, Davis VG, Spagnola NB, Hilt D, Dgetluck N, Ruse S, Patterson TD, Narasimhan M, Harvey PD. Reliability, validity […]

Read More

Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives

by Brittany Scaturro | January 5, 2015 | Publications and Articles

Schizophrenia (SCZ) and psychotic bipolar disorder (PBD) share considerable overlap in clinical features, genetic risk factors and co-occurrence among relatives. The common and unique functional cerebral deficits in these disorders, and in unaffected relatives, remain to be identified. Lui S, Yao L, Xiao Y, Keedy SK, Reilly JL, Keefe RS, Tamminga CA, Keshavan MS, Pearlson […]

Read More

Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A).

by Brittany Scaturro | January 5, 2015 | Publications and Articles

Although cognitive impairment is a core feature of bipolar disorder (BD) there is no instrument of choice for the assessment of bipolar patients. The aim of this study is to assess cognitive performance using the Brief Assessment of Cognition in Affective Disorders (BAC-A), a comprehensive test battery developed specifically for BD, and determine its suitability […]

Read More

Validation of a Computerized Assessment of Functional Capacity

by Brittany Scaturro | December 12, 2014 | Posters

Assessment of functional capacity is critical to the treatment of cognitive impairments in schizophrenia. Current methods are highly correlated with performance on neuropsychological tests, but suffer from compromised ecological validity due to reliance on role playing exercises. RICHARD S. E. KEEFE, STACY A. RUSE, VICKI G. DAVIS, NATHAN SPAGNOLA, ALEXANDRA S. ATKINS, THOMAS L. PATTERSON, […]

Read More

Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder

by Brittany Scaturro | December 6, 2014 | Posters

Evaluate lisdexamfetamine dimesylate (LDX) augmentation of antidepressant monotherapy for executive dysfunction in partially or fully remitted major depressive disorder (MDD). This randomized, placebo-controlled study (NCT00985725) enrolled 143 adults (18-55 years) with mild MDD (Montgomery-Åsberg Depression Rating Scale (MADRS) score ≤ 18) and executive dysfunction (Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Self-Report Global Executive […]

Read More

Refining the latent structure of neuropsychological performance in schizophrenia

by Brittany Scaturro | December 5, 2014 | Publications and Articles

Elucidating the cognitive architecture of schizophrenia promises to advance understanding of the clinical and biological substrates of the illness. Traditional cross-sectional neuropsychological approaches differentiate impaired from normal cognitive abilities but are limited in their ability to determine latent substructure. The current study examined the latent architecture of abnormal cognition in schizophrenia via a systematic approach. […]

Read More

Assessment of Age-Related Differences in Functional Capacity Using the VRFCAT

by Brittany Scaturro | November 23, 2014 | Posters

CTAD Philadelphia, PA, November 20-22 CTAD_VRFCAT_Poster_2014

Read More

Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study

by Brittany Scaturro | November 9, 2014 | Publications and Articles

Familial neuropsychological deficits are well established in schizophrenia but remain less well characterized in other psychotic disorders. This study from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) consortium 1) compares cognitive impairment in schizophrenia and bipolar disorder with psychosis, 2) tests a continuum model of cognitive dysfunction in psychotic disorders, 3) reports familiality of cognitive […]

Read More

Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit

by Brittany Scaturro | November 5, 2014 | Publications and Articles

Difficulty inhibiting context-inappropriate behavior is a common deficit in psychotic disorders. The diagnostic specificity of this impairment, its familiality, and its degree of independence from the generalized cognitive deficit associated with psychotic disorders remain to be clarified. Schizophrenia, schizoaffective and bipolar patients with history of psychosis (n=523), their available first-degree biological relatives (n=656), and healthy […]

Read More

Cultural Adaptation of Translated Neurocognitive Assessments in Russia, Switzerland and Italy: Pilot Testing for a Program to Delay the Onset of Mild Cognitive Impairment due to Alzheimer’s Disease

by Brittany Scaturro | October 14, 2014 | Posters

NeuroCog Trials Receives Distinguished Poster Award from the International Society for CNS Clinical Trials and Methodology NeuroCog Trials’ Senior Scientific Director, Dr. Alexandra S.  Atkins, earned the Distinguished Poster Award at the Autumn conference of the International Society for CNS Clinical Trials and Methodology.  The work was co-authored by an international team of researchers and […]

Read More

Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery

by Brittany Scaturro | October 5, 2014 | Publications and Articles

Clinicians often need to evaluate the treatment response of an individual person and to know that observed change is true improvement or worsening beyond usual week-to-week changes. This paper gives clinicians tools to evaluate individual changes on the MATRICS Consensus Cognitive Battery (MCCB). We compare three different approaches: a descriptive analysis of MCCB test-retest performance […]

Read More

Validation of a Computerized Assessment of Functional Capacity

by Brittany Scaturro | September 24, 2014 | Posters

ACNP Phoenix, AZ, December 7-11 BACKGROUND Assessment of functional capacity is critical to the treatment of cognitive impairments in schizophrenia. Current methods are highly correlated with performance on neuropsychological tests, but suffer from compromised ecological validity due to reliance on role playing exercises. Methods of assessment with improved ecological validity are acutely needed. In response, […]

Read More

Assessment of Age-Related Differences in Functional Capacity Using the VRFCAT

by Pierre Roux | September 23, 2014 | Posters

CTAD Philadelphia, PA, November 20-22 BACKGROUND Reliable evaluation of cognitive performance and functional capacity is critical to the effective assessment of mental health in aging individuals. The Virtual Reality Functional Capacity Assessment Tool (VRFCAT) was developed as a direct performance-based assessment of functional capacity that is sensitive to changes in function across multiple populations. Using […]

Read More

Virtual Reality Functional Capacity Assessment: Progress on the Validation of a Computerized Assessment of Functional Skills

by Pierre Roux | September 22, 2014 | Posters

CNS Summit Boca Raton, FL, November 13-15 BACKGROUND Regulatory guidance for clinical trials targeting cognition in schizophrenia highlights the importance of functional capacity and recommends inclusion of a meaningful functional measure as a co-primary endpoint. We developed the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) as a reliable assessment of functional capacity for use in […]

Read More

The MATRICS Consensus Cognitive Battery: What We Know 6 Years Later

by Pierre Roux | September 21, 2014 | Blog

Following a competitive application process sponsored by the National Institute of Mental Health (NIMH), the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was launched. After 2 years of large consensus meetings, a five-site psychometric and validation study, complex intellectual property agreements, and an endorsement by NIMH and the U.S. Food and […]

Read More

NeuroCog Trials Receives Distinguished Poster Award from the International Society for CNS Clinical Trials and Methodology

by Pierre Roux | September 20, 2014 | Posters

NeuroCog Trials’ Senior Scientific Director, Dr. Alexandra S.  Atkins, earned the Distinguished Poster Award at the Autumn conference of the International Society for CNS Clinical Trials and Methodology for her poster entitled Cultural Adaptation of Translated Neurocognitive Assessments in Russia, Switzerland and Italy: Pilot Testing for a Program to Delay the Onset of Mild Cognitive Impairment […]

Read More

Circadian rhythms in cognitive functioning among patients with schizophrenia

by Pierre Roux | September 19, 2014 | Publications and Articles

Impact on signal detection in clinical trials of potential pro-cognitive therapies. Read more.

Read More

Virtual Reality Functional Capacity Assessment: Progress on the Validation of a Computerized Assessment of Functional Skills

by Pierre Roux | September 17, 2014 | Posters

American Society of Clinical Psychopharmacology Hollywood, Florida, June 16-19 BACKGROUND Assessment of functional capacity is important in the development of treatments for cognitive impairment and may be a part of the overall clinical evaluation in patients with schizophrenia and other CNS disorders. • The Virtual Reality Functional Capacity Assessment Tool (VRFCAT©) is a computer based […]

Read More

Development of a Virtual Reality Assessment of Everyday Living Skills

by Brittany Scaturro | September 16, 2014 | Publications and Articles

Cognitive impairments affect the majority of patients with schizophrenia and these impairments predict poor long term psychosocial outcomes.  Treatment studies aimed at cognitive impairment in patients with schizophrenia not only require demonstration of improvements on cognitive tests, but also evidence that any cognitive changes lead to clinically meaningful improvements.  Measures of “functional capacity” index the […]

Read More

A Comparison of Cross-Cultural Regional Norms for the MATRICS Consensus Cognitive Battery (MCCB)

by Pierre Roux | September 14, 2014 | Posters

An examination of differences between MCCB overall composite scores calculated using standard U.S. norms and those calculated using regional normative data sets. Ioan Stroescu , Vicki G Davis , Alexandra S Atkins, & Richard SE Keefe View Poster

Read More

Cognition and motivation as treatment targets in schizophrenia

by Brittany Scaturro | September 6, 2014 | Publications and Articles

Motivational deficits and cognitive test performance in schizophrenia. [JAMA Psychiatry. 2014] Keefe RSE. Cognition and motivation as treatment targets in schizophrenia.  JAMA Psychiatry, 2014, 71(9): 987-988.

Read More

Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia

by Brittany Scaturro | September 5, 2014 | Publications and Articles

Preclinical and clinical data suggest that pregnenolone may be a promising therapeutic in schizophrenia. Pregnenolone is neuroprotective and enhances learning and memory, myelination, and microtubule polymerization. Treatment with pregnenolone elevates allopregnanolone (a neurosteroid that enhances GABAA receptor responses) and pregnenolone sulfate (a positive NMDA receptor modulator). Pregnenolone could thus potentially mitigate GABA dysregulation and/or NMDA […]

Read More

Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories

by Brittany Scaturro | September 5, 2014 | Publications and Articles

Elevated antisaccade error rate, reflecting problems with inhibitory behavioral control, is a promising intermediate phenotype for schizophrenia. Here, we consider whether it marks liability across psychotic disorders via common or different neurophysiological mechanisms and whether it represents a neurocognitive risk indicator apart from the generalized cognitive deficit. Reilly JL, Frankovich K, Hill SK, Gershon E, […]

Read More

Regressing to prior response preference after set switching implicates striatal dysfunction across psychotic disorders: Findings from the B-SNIP study

by Brittany Scaturro | September 5, 2014 | Publications and Articles

Difficulty switching behavioral response sets is established in psychotic disorders. In rodent models, prefrontal lesions cause difficulty initially switching to new response sets (perseverative errors) while striatal lesions cause difficulty suppressing responses to previous choice preferences (regressive errors). Hill SK, Reilly JL, Ragozzino ME, Rubin LH, Bishop JR, Gur RC, Gershon ES, Tamminga CA, Pearlson […]

Read More

Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review

by Brittany Scaturro | August 9, 2014 | Publications and Articles

Cognitive impairment frequently accompanies major depressive disorder (MDD) and can persist during remission. This review examined pharmacotherapy effects on cognitive function in MDD Keefe RSE, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder:  A systemic review.  Journal of Clinical Psychiatry, 2014; 75(8): 864-876.

Read More

Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies

by Brittany Scaturro | August 6, 2014 | Publications and Articles

Cognition is affected by circadian rhythms over the course of a day. Circadian rhythms in cognitive functioning are driven by a variety of both endogenous and exogenous factors. Patients with schizophrenia are known to have disturbed circadian rhythms that can affect their cognitive functioning. Hufford MR, Davis VG, Hilt D, Dgetluck N, Geffen Y, Loebel A, […]

Read More

Brief assessment of cognition in schizophrenia: normative data in an English-speaking ethnic Chinese sample

by Brittany Scaturro | August 1, 2014 | Publications and Articles

There is a dearth of non-Western normative data for neuropsychological batteries designed to measure cognitive deficits in schizophrenia. Here, we provide normative data for English-speaking ethnic Chinese on the widely used Brief Assessment of Cognition in Schizophrenia acquired from 595 healthy community participants between ages 14 and 55. Means and standard deviations of subtests and […]

Read More

Virtual Reality Functional Capacity Assessment In Schizophrenia: Preliminary data regarding diagnostic differences and correlations with cognitive performance.

by Brittany Scaturro | July 5, 2014 | Publications and Articles

Assessment of functional capacity is an intrinsic part of determining the functional relevance of response to treatment of cognitive impairment in schizophrenia. Existing methods are highly and consistently correlated with performance on neuropsychological tests, but most current assessments of functional capacity are still paper and pencil simulations. We developed a computerized virtual reality assessment that […]

Read More

Virtual Reality Functional Capacity Assessment: Progress on the Validation of a Computerized Assessment of Functional Skills

by Brittany Scaturro | June 20, 2014 | Posters

American Society of Clinical Psychopharmacology Hollywood, Florida, June 16-19 NCDEU-VRFCAT-2014

Read More

Cognitive Deficits in Bipolar Depression Measured With the Brief Assessment of Cognition in Affective Disorders (BAC-A)

by Brittany Scaturro | May 11, 2014 | Publications and Articles

Cognitive deficits in bipolar disorder are significant enough to impact everyday functioning. A key question for treatments aimed at cognition is which cognitive domains are most affected by bipolar disorder and which cognitive tests have the best psychometric characteristics for this population. Keefe RS, Fox KH, Davis VG, Kennel C, Walker TM, Burdick KE, Harvey […]

Read More

Development of a virtual reality assessment of everyday living skills

by Brittany Scaturro | April 23, 2014 | Publications and Articles

Cognitive impairments affect the majority of patients with schizophrenia and these impairments predict poor long term psychosocial outcomes.  Treatment studies aimed at cognitive impairment in patients with schizophrenia not only require demonstration of improvements on cognitive tests, but also evidence that any cognitive changes lead to clinically meaningful improvements. Ruse SA, Davis VG, Atkins AS, […]

Read More

Virtual reality functional capacity assessment in schizophrenia: Preliminary data regarding feasibility and correlations with cognitive and functional capacity performance

by Brittany Scaturro | March 12, 2014 | Publications and Articles

Assessment of functional capacity is an intrinsic part of determining the functional relevance of response to treatment of cognitive impairment in schizophrenia. Existing methods are highly and consistently correlated with performance on neuropsychological tests, but most current assessments of functional capacity are still paper and pencil simulations. We developed a computerized virtual reality assessment that […]

Read More

A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia

by Brittany Scaturro | January 27, 2014 | Publications and Articles

Effective treatments for cognitive impairment associated with schizophrenia (CIAS) remain an unmet need. Nicotinic α7 receptor agonists may be effective in CIAS. This 8-week (week 1, inpatient; weeks 2-8, outpatient), double-blind, randomized study used Measurement And Treatment Research to Improve Cognition in Schizophrenia (MATRICS) guidelines to investigate the nicotinic α7 partial agonist RG3487 (formerly MEM3454) […]

Read More

Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study

by Brittany Scaturro | January 9, 2014 | Publications and Articles

Despite the widespread belief that neuropsychological decline is a cardinal feature of the progression from the premorbid stage to the chronic form of schizophrenia, few longitudinal studies have examined change in neuropsychological functioning from before to after illness onset. The authors examined whether neuropsychological decline is unique to schizophrenia, whether it is generalized or confined […]

Read More

Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia

by Brittany Scaturro | November 5, 2013 | Publications and Articles

A number of pharmacological agents for treating negative symptoms in schizophrenia are currently in development. Unresolved questions regarding the design of clinical trials in this area were discussed at an international meeting in Florence, Italy in April 2012. Participants included representatives from academia, the pharmaceutical industry, and the European Medicines Agency (EMA). Marder SR, Alphs […]

Read More

Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls

by Brittany Scaturro | October 31, 2013 | Publications and Articles

The Brief Assessment of Cognition in Schizophrenia (BACS) is designed for assessment of cognitive function in patients with schizophrenia. Versions of the BACS in English and other languages have been shown to be as sensitive to cognitive dysfunction as a standard test battery, with the advantage of brief administration and scoring time. The present study […]

Read More

Schizophrenia is a cognitive illness: time for a change in focus

by Brittany Scaturro | October 9, 2013 | Publications and Articles

Schizophrenia is currently classified as a psychotic disorder. This article posits that this emphasis on psychosis is a conceptual fallacy that has greatly contributed to the lack of progress in our understanding of this illness and hence has hampered the development of adequate treatments. Not only have cognitive and intellectual underperformance consistently been shown to […]

Read More

Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials

by Brittany Scaturro | May 10, 2013 | Publications and Articles

This article captures the proceedings of a meeting aimed at defining clinically meaningful effects for use in randomized controlled trials for psychopharmacological agents. Keefe RS, Kraemer HC, Epstein RS, Frank E, Haynes G, Laughren TP, McNulty J, Reed SD, Sanchez J, Leon AC. Defining a clinically meaningful effect for the design and interpretation of randomized […]

Read More

How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS

by Brittany Scaturro | May 5, 2013 | Publications and Articles

Interview-based scales can be used as coprimary measures to complement the assessment of cognitive impairment in schizophrenia. One major question that arises from the use of such tools is how specific they are in relation to other psychopathological domains. We analyse the specificity of the Positive and Negative Syndrome Scale (PANSS) negative subscale and the […]

Read More

The Cognitive Assessment Interview (CAI): Reliability and validity of a brief interview-based measure of cognition

by Brittany Scaturro | May 5, 2013 | Publications and Articles

To obtain Food and Drug Administration approval for the treatment of cognitive impairments associated with schizophrenia, a drug will need to demonstrate benefits beyond those that may be documented on objective cognitive tests. Interview-based measures of cognition such as the Cognitive Assessment Interview (CAI) are candidate coprimary outcome measures. Ventura J, Reise SP, Keefe RSE, […]

Read More

The course of cognitive functioning over six months in individuals at clinical high risk for psychosis

by Brittany Scaturro | April 30, 2013 | Publications and Articles

Cognitive impairment is common in psychosis and has recently been observed in individuals at clinical high risk (CHR) of developing psychosis. The purpose of this study was to characterize longitudinal change in cognition among CHR individuals, and compare cognition of CHR individuals who later convert to psychosis to that of CHR who do not convert. […]

Read More

Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care

by Brittany Scaturro | March 17, 2013 | Publications and Articles

The Schizophrenia Cognition Rating Scale (SCoRS), an interview-based assessment of cognition, has proved to be a valid measure of cognitive performance in patients with schizophrenia. Vita A, Deste G, Barlati S, De Peri L, Giambra A, Poli R, Keefe RSE, Sacchetti E. Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) […]

Read More

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: What have we learned so far?

by Brittany Scaturro | March 5, 2013 | Publications and Articles

In light of the number of studies conducted to examine the treatment of cognitive impairment associated with schizophrenia (CIAS), we critically reviewed recent CIAS trials. Trials were identified through searches of the website “www.clinicaltrials.gov” using the terms “schizophrenia AND cognition,” “schizophrenia AND neurocognition,” “schizophrenia AND neurocognitive tests,” “schizophrenia AND MATRICS,” “schizophrenia AND MCCB,” “schizophrenia AND […]

Read More

Applicability of the MATRICS Consensus Cognitive Battery in Singapore

by Brittany Scaturro | January 30, 2013 | Publications and Articles

The MATRICS Consensus Cognitive Battery (MCCB) was developed to provide a reliable, valid, and standard battery for clinical trials on cognitive enhancers in schizophrenia. In this study we tested the applicability of the MCCB to Singapore’s English speakers. Healthy ethnic Chinese, Malay, and Indian English speakers (N = 171) of both genders were recruited within […]

Read More

Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: A 13-week, randomized, placebo-controlled, crossover trial

by Brittany Scaturro | January 1, 2013 | Publications and Articles

Patients were randomly assigned to receive milnacipran or placebo for 6 weeks, followed by a 1-week washout and then crossover to the other arm for another 6 weeks. The overall trial lasted 13 weeks and was conducted between July 2011 and May 2013. Assessments were performed at each visit. Kim JL, Rele S, Marks DM, […]

Read More

Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia

by Brittany Scaturro | December 20, 2012 | Publications and Articles

The Reasons for Antipsychotic Discontinuation Questionnaire (RAD-Q) was designed to assess clinicians’ perceptions of reasons for antipsychotic discontinuation or continuation. The current study examined psychometric properties of this instrument and patterns of antipsychotic discontinuation. The sample of 121 patients (81 discontinuation, 40 continuation) with schizophrenia or schizoaffective disorder was 66.9% male, with a mean age […]

Read More

Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study

by Brittany Scaturro | December 5, 2012 | Publications and Articles

The Continuous Performance Test (CPT) has emerged as the most commonly administered measure of sustained attention, but use of discrepant versions reduces the ability of researchers and clinicians to accurately draw cross-study conclusions. In an effort to standardize use of the CPT, this study compared four versions of the Identical Pairs CPT for their reliability […]

Read More

Circadian Rhythms and Cognition: Using Time of Day Effects To Enhance Signal Detection in Clinical Trials of Pro-Cognitive Therapies for Schizophrenia

by Brittany Scaturro | September 24, 2012 | Publications and Articles

Circadian Rhythms and Cognition: Using Time of Day Effects To Enhance Signal Detection in Clinical Trials of Pro-Cognitive Therapies for Schizophrenia. M Hufford, V Davis, N Dgetluck, M Gawryl, D Hilt, A Rappaport, R Keefe. Poster presentation at the International Society for CNS Clinical Trials and Methodology 2012 Autumn Conference, October 2012, Los Angeles, CA. […]

Read More

Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study

by Brittany Scaturro | September 13, 2012 | Publications and Articles

BL-1020 is a γ-aminobutyric acid (GABA)-enhanced antipsychotic that combines dopamine antagonism with GABA agonist activity. On the basis of animal models, we tested the hypotheses that BL-1020 would be effective in ameliorating both psychotic symptoms and cognitive impairments, with a favorable safety profile in acutely ill schizophrenia patients. Geffen Y, Keefe R, Rabinowitz J, Anand […]

Read More

Persistent cannabis users show neuropsychological decline from childhood to midlife

by Brittany Scaturro | July 30, 2012 | Publications and Articles

Recent reports show that fewer adolescents believe that regular cannabis use is harmful to health. Concomitantly, adolescents are initiating cannabis use at younger ages, and more adolescents are using cannabis on a daily basis. The purpose of the present study was to test the association between persistent cannabis use and neuropsychological decline and determine whether […]

Read More

Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial

by Brittany Scaturro | May 15, 2012 | Publications and Articles

The true benefit of pharmacologic intervention to improve cognition in schizophrenia may not be evident without regular cognitive enrichment. Clinical trials assessing the neurocognitive effects of new medications may require engagement in cognitive remediation exercises to stimulate the benefit potential. However, the feasibility of large-scale multisite studies using cognitive remediation at clinical trials sites has […]

Read More

Computerized Functional Capacity Assessment in Schizophrenia: Evidence for Convergent Validity

by Pierre Roux | April 24, 2012 | Posters

The International Society for CNS Clinical Trials and Methodology Washington, DC, February 21-23 BACKGROUND Assessment of functional capacity is an intrinsic part of the treatment of cognitive impairments in schizophrenia. The Virtual Reality Functional Capacity Assessment Tool (VRFCAT©) is a computer based virtual reality measure of functional capacity that relies on a realistic simulated environment […]

Read More

Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia

by Brittany Scaturro | April 6, 2012 | Publications and Articles

Auditory emotion recognition impairments in schizophrenia: relationship to acoustic features and cognition. [Am J Psychiatry. 2012] A new perspective on anhedonia in schizophrenia. [Am J Psychiatry. 2012] Keefe RSE, Kraus MS. Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia.  American Journal of Psychiatry, 2012; 169 (4): 354-357.

Read More

Methodological Issues Affecting Signal Detection in a Clinical Trial for Cognitive Impairment in Schizophrenia

by Brittany Scaturro | February 25, 2012 | Posters

M Hufford, M Gawryl, N Dgetluck, V Davis, S Murray, R Keefe, D Hilt.  Poster presentation at the International Society for CNS Clinical Trials and Methodology 8th Annual Scientific Meeting, February 2012, Washington, D.C. View Poster

Read More

Guide to Assessment Scales in Schizophrenia

by Brittany Scaturro | January 1, 2012 | Publications and Articles

This book provides a wealth of assessment instruments from the world’s experts to help clinicians gather the most important information from their patients. This is the 3rd edition of our highly successful guides to Rating Scales in Schizophrenia, it is a practical and quick reference publication for psychiatrists. http://www.springer.com/us/book/9781908517524

Read More

Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial

by Brittany Scaturro | December 31, 2011 | Publications and Articles

The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Project produced a battery of tests, the MATRICS Consensus Cognitive Battery (MCCB), designed to assess cognitive treatment effects in clinical trials of patients with schizophrenia. In validation studies, the MCCB demonstrated excellent reliability, minimal practice effects and significant correlations with measures of functional capacity. […]

Read More

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia

by Brittany Scaturro | December 12, 2011 | Publications and Articles

Cognitive dysfunction is a key predictor of functional disability in schizophrenia. Davunetide (AL-108, NAP) is an intranasally administered peptide currently being developed for treatment of Alzheimer’s disease and related disorders. This study investigates effects of davunetide on cognition in schizophrenia. Javitt DC, Buchanan RW, Keefe RSE, Kern R, McMahon RP, Green MF, Lieberman J, Goff […]

Read More

The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: What do we know 5 years later?

by Brittany Scaturro | November 5, 2011 | Publications and Articles

The Food and Drug Administration (FDA)-National Institute of Mental Health (NIMH)-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) clinical trial guidelines for cognitive-enhancing drugs in schizophrenia and the MATRICS Consensus Cognitive Battery (MCCB) were designed to facilitate novel compound development in the treatment of cognitive impairments. Buchanan RW, Keefe RSE, Umbricht D, Green […]

Read More

The virtual reality functional capacity assessment tool (VRFCAT): A new co-primary measure for schizophrenia drug trials.

by Pierre Roux | September 24, 2011 | Posters

Presented at the annual meetings of: The International Society for CNS Clinical Trials, Washington, DC New Clinical Drug Evaluation Unit (National Institute of Mental Health), Boca Raton, FL. BACKGROUND Representatives from FDA have repeatedly stated that improvement on traditional measures of cognition will not be sufficient for approval of a new drug for cognitive enhancement. […]

Read More

Report from the Working Group Conference on multi-site trial design for cognitive remediation in schizophrenia. Schizophrenia Bulletin

by Brittany Scaturro | September 5, 2011 | Publications and Articles

The National Institute of Mental Health (NIMH)-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Project and related efforts have stimulated the initiation of several studies of pharmacologic treatments for cognitive impairment in schizophrenia. Cognitive remediation may provide an excellent platform for the provision of new learning opportunities and the acquisition of new skills […]

Read More

The MATRICS Consensus Cognitive Battery in Patients with bipolar I disorder

by Brittany Scaturro | July 5, 2011 | Publications and Articles

The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was devised to identify a neurocognitive battery to be used in clinical trials targeting cognition in schizophrenia, a process, which resulted in the MATRICS Consensus Cognitive Battery (MCCB). The MCCB has been selected by the United States Food and Drug Administration to be […]

Read More

Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD

by Brittany Scaturro | May 15, 2011 | Publications and Articles

The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer’s disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study (CATIE-AD). Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer DL, Stroup TS, Dagerman […]

Read More

Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone

by Brittany Scaturro | April 5, 2011 | Publications and Articles

Improving cognitive functioning in people with schizophrenia is a major treatment goal. In addition, interview-based measures have been developed to supplement performance-based assessments. However, few data are available regarding whether interview-based measures are sensitive to treatment-related changes. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in […]

Read More

Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls

by Brittany Scaturro | March 5, 2011 | Publications and Articles

Neurocognitive impairment is a core feature of schizophrenia and is closely associated with functional outcome. The importance of cognitive assessment is broadly accepted today, and an easy-to-use, internationality validated cognitive assessment tool is needed by researchers and in daily clinical practice. Segarra N, Bernardo M, Gutierrez F, Justicia A, Fernandez-Egea E, Allas M, Safont G, […]

Read More

Validation of the German Version of the Brief Assessment of Cognition in Schizophrenia (BACS) – Preliminary Results

by Brittany Scaturro | March 5, 2011 | Publications and Articles

The German version of the BACS showed high test-retest reliability. Sensitivity and specificity scores demonstrated good ability to differentiate between patients and controls. The study suggests that the German Version of the BACS is a useful scale to evaluate cognitive functioning. Sachs G, Winklbaur B, Jagsch R, Keefe RS. Validation of the German Version of […]

Read More

Methodological issues in negative symptom trials

by Brittany Scaturro | March 5, 2011 | Publications and Articles

Individuals from academia, the pharmaceutical industry, and the US Food and Drug Administration used a workshop format to discuss important methodological issues in the design of trials of pharmacological agents for improving negative symptoms in schizophrenia. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RSE. Methodological issues in negative symptom trials.  Schizophrenia Bulletin, 2011; […]

Read More

Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia

by Brittany Scaturro | March 5, 2011 | Publications and Articles

A psychometric analysis of 2 interview-based measures of cognitive deficits was conducted: the 21-item Clinical Global Impression of Cognition in Schizophrenia (CGI-CogS; Ventura et al., 2008), and the 20-item Schizophrenia Cognition Rating Scale (SCoRS; Keefe et al., 2006), which were administered on 2 occasions to a sample of people with schizophrenia. Traditional psychometrics, bifactor analysis, […]

Read More

The MCCB impairment profile for schizophrenia outpatients: Results from the MATRICS psychometric and standardization study

by Brittany Scaturro | March 5, 2011 | Publications and Articles

The MATRICS Psychometric and Standardization Study was conducted as a final stage in the development of the MATRICS Consensus Cognitive Battery (MCCB). The study included 176 persons with schizophrenia or schizoaffective disorder and 300 community residents. Data were analyzed to examine the cognitive profile of clinically stable schizophrenia patients on the MCCB. Secondarily, the data […]

Read More

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

by Brittany Scaturro | March 1, 2011 | Publications and Articles

In a previous pilot study, MK-0777–a γ-aminobutyric acid (GABA)(A) α2/α3 partial agonist–was reported to improve delayed memory and cognitive measures of prefrontal cortical function in people with schizophrenia. The current study was designed to further examine the efficacy and safety of MK-0777 for the treatment of cognitive impairments in schizophrenia. Buchanan RW, Keefe RS, Lieberman […]

Read More

Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia

by Brittany Scaturro | January 1, 2011 | Publications and Articles

Cognitive deficits present in almost all patients with schizophrenia, and account for considerable functional disability, but as typically measured in schizophrenia are unrelated to hallucinations and delusions. Keefe RSE, Kraus MS, Krishnan RR. Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia.  Neuropsychopharmacology, 2011; 36(1): 367-380.  (PMCID:  PMC3055500).

Read More

Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: A 4-week, double-blind, placebo-controlled study

by Brittany Scaturro | November 5, 2010 | Publications and Articles

This 4-week, randomized, double-blind, placebo-controlled, proof-of-concept study was conducted between July and December 2007. Patients had a history of stable schizophrenia (DSM-IV-TR criteria) for ≥ 8 weeks and were treated with oral risperidone, olanzapine, or paliperidone for ≥ 6 weeks at stable doses for ≥ 4 weeks. Kane JM, D’Souza DC, Patkar AA, Youakim JM, […]

Read More

Differential effects of emotional information on interference task performance across the life span

by Brittany Scaturro | September 30, 2010 | Publications and Articles

While functioning in multiple domains declines with age, emotional regulation appears to remain preserved in older adults. The Emotion Inhibition (Emotional Stroop) Test requires participants to name the ink color in which neutrally and emotionally valenced words are printed. It was employed in the current investigation as a measure of affective regulation in the context […]

Read More

The Cognitive Assessment Interview (CAI): Development and validation of an empirically derived, brief interview-based measure of cognition

by Brittany Scaturro | August 3, 2010 | Publications and Articles

Practical, reliable “real world” measures of cognition are needed to supplement neurocognitive performance data to evaluate possible efficacy of new drugs targeting cognitive deficits associated with schizophrenia. Because interview-based measures of cognition offer one possible approach, data from the MATRICS initiative (n=176) were used to examine the psychometric properties of the Schizophrenia Cognition Rating Scale […]

Read More

The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia

by Brittany Scaturro | June 30, 2010 | Publications and Articles

Growing interest in cognitive deficits associated with schizophrenia has led to the need for a clinician-friendly cognitive instrument. The Schizophrenia Cognition Rating Scale (SCoRS), recognized for its brevity and ease of administration, has proven to be a valid and reliable measure of overall cognition in schizophrenia patients. However, there has been no such validation in […]

Read More

Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis

by Brittany Scaturro | June 4, 2010 | Publications and Articles

Early detection and prospective evaluation of clinical high-risk (CHR) individuals who may develop schizophrenia or other psychotic disorders is critical for predicting psychosis onset and for testing preventive interventions. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, […]

Read More

Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis

by Brittany Scaturro | June 3, 2010 | Publications and Articles

Early detection and prospective evaluation of clinical high-risk (CHR) individuals who may develop schizophrenia or other psychotic disorders is critical for predicting psychosis onset and for testing preventive interventions. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, […]

Read More

Circumstances under which practice does not make perfect: A review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies

by Brittany Scaturro | April 4, 2010 | Publications and Articles

In this article, we review the literature on practice effects in schizophrenia, an underappreciated confound in interpreting cognitive improvement in clinical trials. We first examine claims regarding first- and second-generation antipsychotic medications as cognitive enhancers, and follow it with a discussion of recent studies demonstrating how practice or placebo effects may drive ‘positive’ findings. Thus, […]

Read More

Proof-of-Concept Trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

by Brittany Scaturro | July 3, 2009 | Publications and Articles

The neurosteroid pregnenolone and its sulfated derivative enhance learning and memory in rodents. Pregnenolone sulfate also positively modulates NMDA receptors and could thus ameliorate hypothesized NMDA receptor hypofunction in schizophrenia. Furthermore, clozapine increases pregnenolone in rodent hippocampus, possibly contributing to its superior efficacy. We therefore investigated adjunctive pregnenolone for cognitive and negative symptoms in patients […]

Read More

Cognitive effects of antipsychotics drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST)

by Brittany Scaturro | June 3, 2009 | Publications and Articles

Cognitive impairment, manifested as mild to moderate deviations from psychometric norms, is present in many but not all schizophrenia patients. The purpose of the present study was to compare the effect of haloperidol with that of second-generation antipsychotic drugs on the cognitive performance of patients with schizophreniform disorder or first-episode schizophrenia. Davidson M, Galderisi S, […]

Read More

Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study.

by Brittany Scaturro | October 2, 2008 | Publications and Articles

There is uncertainty regarding the onset timing of the cognitive deficiencies of schizophrenia. We investigated whether conversion to psychosis and/or olanzapine altered the neuropsychological course of subjects within the first-ever double blind medication study of the putative schizophrenia first episode prodrome. Hawkins KA, Keefe RSE, Christensen B, Addington J, Woods SW, Callahan J, Zipursky RB, […]

Read More

Relationship of cognition and psychopathology to functional impairment in schizophrenia

by Brittany Scaturro | August 2, 2008 | Publications and Articles

This study evaluated the association of neurocognition and symptoms with measures of social and occupational functioning in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RSE. Relationship of cognition and psychopathology to function impairment in schizophrenia.  The American Journal of Psychiatry, 2008; 165(8): 978-987.

Read More

Norms and standardization of the Brief Assessment of Cognition in Schizophrenia

by Brittany Scaturro | July 2, 2008 | Publications and Articles

According to the recommendations of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Neurocognition Committee, one of the desired characteristics of a cognitive battery for assessing cognition in schizophrenia studies and clinical trials is the availability of normative data. Keefe RSE, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, Hawkins […]

Read More

Implementation considerations for multisite clinical trials with cognitive neuroscience tasks

by Brittany Scaturro | May 20, 2008 | Publications and Articles

Multisite clinical trials aimed at cognitive enhancement across various neuropsychiatric conditions have employed standard neuropsychological tests as outcome measures. While these tests have enjoyed wide clinical use and have proven reliable and predictive of functional disability, a number of implementation challenges have arisen when these tests are used in clinical trials. Keefe RSE, Harvey PD. […]

Read More

Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia

by Brittany Scaturro | March 14, 2008 | Publications and Articles

Efficient and reliable assessments of cognitive treatment effects are essential for the comparative evaluation of procognitive effects of pharmacologic therapies. Yet, no studies have addressed the sensitivity and efficiency with which neurocognitive batteries evaluate cognitive abilities before and after treatment. Hill SK, Sweeney JA, Hamer RM, Keefe RSE, Perkins DO, Gu H, McEvoy JP, Lieberman […]

Read More

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity

by Brittany Scaturro | January 2, 2008 | Publications and Articles

The lack of an accepted standard for measuring cognitive change in schizophrenia has been a major obstacle to regulatory approval of cognition-enhancing treatments. A primary mandate of the National Institute of Mental Health’s Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was to develop a consensus cognitive battery for clinical trials of […]

Read More

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization

by Brittany Scaturro | January 2, 2008 | Publications and Articles

The consensus cognitive battery developed by the National Institute of Mental Health’s (NIMH’s) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative includes 10 independently developed tests that are recommended as the standard battery for clinical trials of cognition-enhancing interventions for schizophrenia. To facilitate interpretation of results from the MATRICS Consensus Cognitive Battery […]

Read More

Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study

by Brittany Scaturro | January 2, 2008 | Publications and Articles

During the consensus meetings of the National Institute of Mental Health Measurement and Treatment Research to Improve Cognition in Schizophrenia (NIMH-MATRICS) Initiative, the U.S. Food and Drug Administration took the position that a drug for this purpose should show changes on 1) an accepted consensus cognitive performance measure and 2) an additional measure (i.e., a […]

Read More

Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials

by Brittany Scaturro | December 15, 2007 | Publications and Articles

Lamotrigine previously was found to attenuate ketamine-induced behavioral changes and, in 2 placebo-controlled trials, to improve psychosis when added to antipsychotic medication. We sought to evaluate the potential role of lamotrigine augmentation in schizophrenia patients resistant to atypical antipsychotic medication. Goff DC, Keefe RSE, Citrome L, Davy K, Krystal J, Large C, Volayka J, Webster […]

Read More

Brief Assessment of Cognition in Schizophrenia: Validation of the Japanese version

by Brittany Scaturro | December 2, 2007 | Publications and Articles

This preliminary study was performed to test the reliability and validity of the Brief Assessment of Cognition in Schizophrenia (BACS) as an assessment tool in a Japanese-language version (BACS-J). The subjects for the present study were 30 outpatients with chronic schizophrenia. Each subject gave written informed consent to participate in the research. Kaneda Y, Sumiyoshi […]

Read More

Cognition as an outcome measure in schizophrenia

by Brittany Scaturro | August 14, 2007 | Publications and Articles

Cognitive deficits are a core feature of schizophrenia. These deficits are not caused by medication or symptoms, and have a dramatic negative effect on real-world functioning. Kraus MS, Keefe RSE. Cognition as an outcome measure in schizophrenia.  British Journal of Psychiatry, 2007; 50: 46-51.  

Read More

Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison

by Brittany Scaturro | July 14, 2007 | Publications and Articles

The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis. Keefe RSE, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis:  A randomized, double-blind 52 week comparison.  The American Journal […]

Read More

Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial

by Brittany Scaturro | July 11, 2007 | Publications and Articles

Altered expression of central muscarinic and nicotinic acetylcholine receptors in hippocampal and cortical regions may contribute to the cognitive impairment exhibited in patients with schizophrenia. Increasing cholinergic activity through the use of a cholinesterase inhibitor (ChEI) therefore represents a possible strategy for cognitive augmentation in schizophrenia. Keefe RSE, Malhotra AK, Meltzer H, Kane JM, Buchanan […]

Read More

Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS)

by Brittany Scaturro | July 2, 2007 | Publications and Articles

Cognitive assessment in schizophrenia has traditionally used batteries that are long and complex or differ widely in their content. The Brief Assessment of Cognition in Schizophrenia (BACS) has been developed to cover the main cognitive deficits of schizophrenia as well as to be easily and briefly administered, portable, sensitive and reliable. Salgado JV, Carvalhaes CFR, […]

Read More

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial

by Brittany Scaturro | June 14, 2007 | Publications and Articles

Neurocognitive impairment in schizophrenia is severe and is an important predictor of functional outcome. The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, […]

Read More

How should DSM-V criteria for schizophrenia include cognitive impairment?

by Brittany Scaturro | June 13, 2007 | Publications and Articles

Neurocognitive impairment is considered a core component of schizophrenia and is increasingly under investigation as a potential treatment target. On average, cognitive impairment is severe to moderately severe compared with healthy controls, and almost all patients with schizophrenia demonstrate cognitive decrements compared with their expected level if they had not developed the illness. Keefe RSE, […]

Read More

A longitudinal study of neurocognitive function in individuals at-risk for psychosis

by Brittany Scaturro | December 2, 2006 | Publications and Articles

Clinically defined prodromal diagnostic criteria identify at-risk individuals with a 35-40% likelihood of developing a psychotic disorder within a year. The time course and predictive value of cognitive deficits in the development of psychosis has not been established. Keefe RSE, Perkins DO, Gu H, Zipursky RB, Christensen BK, Lieberman JA. A longitudinal study of neurocognitive […]

Read More

Baseline neurocognitive deficits in the CATIE schizophrenia trial

by Brittany Scaturro | September 15, 2006 | Publications and Articles

Neurocognition is moderately to severely impaired in patients with schizophrenia. However, the factor structure of the various neurocognitive deficits, the relationship with symptoms and other variables, and the minimum amount of testing required to determine an adequate composite score has not been determined in typical patients with schizophrenia. Keefe RSE, Bilder RM, Harvey PD, Davis […]

Read More

The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity

by Brittany Scaturro | March 2, 2006 | Publications and Articles

Interview-based measures of cognition may serve as potential coprimary measures in clinical trials of cognitive-enhancing drugs for schizophrenia. However, there is no such valid scale available. Interviews of patients and their clinicians are not valid in that they are unrelated to patients’ levels of cognitive impairment as assessed by cognitive performance tests. This study describes […]

Read More

The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome

by Brittany Scaturro | February 15, 2006 | Publications and Articles

The Brief Assessment of Cognition in Schizophrenia (BACS) assesses five different domains of cognitive function with six tests, and takes about 30-35 minutes to complete in patients with schizophrenia. Previous work has demonstrated the reliability of this measure, and its sensitivity to the deficits of schizophrenia. However, the relationship of this brief cognitive measure to […]

Read More

One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia

by Brittany Scaturro | January 1, 2006 | Publications and Articles

Neurocognitive deficits in schizophrenia can reach 1 to 2 standard deviations below healthy controls. The comparative effect of typical and atypical antipsychotic medications on neurocognition is controversial, and based primarily on studies with small samples and large doses of typical comparator medications. The present study assessed neurocognitive efficacy. Keefe RSE, Young CA, Rock SL, Purdon […]

Read More

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

by Brittany Scaturro | September 22, 2005 | Publications and Articles

The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe […]

Read More

Research with spanish-speaking populations in the United States: lost in the translation. A commentary and a plea

by Brittany Scaturro | July 2, 2005 | Publications and Articles

Verbal material used to assess the cognitive abilities of Spanish-speakers in the the United States is frequently of linguistically unacceptable quality. The use of these materials in research settings is thought to pose a serious threat to test validity and hence to the validity of claimed results or conclusions. The authors explain how and why […]

Read More

Defining a cognitive function decrement in schizophrenia

by Brittany Scaturro | March 15, 2005 | Publications and Articles

Although cognitive impairment is described as a core component of the characterization of schizophrenia, a sizable percentage of patients are classified as unimpaired by traditional definitions of impairment. The purpose of this study was to determine the percentage of patients with schizophrenia meeting criteria for a “cognitive function decrement” defined as a current level of […]

Read More

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia

by Brittany Scaturro | January 16, 2005 | Publications and Articles

On April 23, 2004, a joint meeting of the FDA, NIMH, MATRICS investigators, and experts from academia and the pharmaceutical industry was convened to develop guidelines for the design of clinical trials of cognitive-enhancing drugs for neurocognitive impairments in patients with schizophrenia. Buchanan RW, Davis M, Goff D, Green MF, Keefe RSE, Leon A, Nuechterlein […]

Read More

Cognitive impairment as a target for pharmacological treatment in schizophrenia

by Brittany Scaturro | December 6, 2004 | Publications and Articles

Cognitive impairment has emerged as an important new target in schizophrenia therapeutics in light of evidence that cognitive deficits are critically related to the functional of disability that is characteristic of the illness. Evidence is briefly reviewed supporting the idea that the cognitive impairment in schizophrenia is an attractive target for therapeutic intervention including: (1) […]

Read More

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria

by Brittany Scaturro | September 1, 2004 | Publications and Articles

To stimulate the development of new drugs for the cognitive deficits of schizophrenia, the National Institute of Mental Health (NIMH) established the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative. This article presents an overview of decisions from the first MATRICS consensus conference. The goals of the meeting were to 1) identify […]

Read More

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

by Brittany Scaturro | June 16, 2004 | Publications and Articles

The effect of antipsychotic medication on neurocognitive function remains controversial, especially since most previous work has compared the effects of novel antipsychotic medications with those of high doses of conventional medications. This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis. Keefe RSE, Seidman LJ, Christensen BK, […]

Read More

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery

by Brittany Scaturro | June 1, 2004 | Publications and Articles

Studies of neurocognitive function in patients with schizophrenia use widely variable assessment techniques. Clinical trials assessing the cognitive enhancing effect of new medications have used neurocognitive assessment batteries that differed in content, length and administration procedures. The Brief Assessment of Cognition in Schizophrenia (BACS) is a newly developed instrument that assesses the aspects of cognition […]

Read More

Neuropsychological status of subjects at high risk for a first episode of psychosis

by Brittany Scaturro | April 1, 2004 | Publications and Articles

Thirty-six subjects aged 16 years or older judged at risk for a first episode of psychosis within a North American multi-site study of the schizophrenia prodrome [McGlashan et al., Schizophr. Res. (2003); Miller et al., Schizophr. Res. (2003)] performed at levels intermediate to population norms and data reported for schizophrenia samples on a comprehensive neuropsychological […]

Read More

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

by Brittany Scaturro | February 15, 2001 | Publications and Articles

Novel antipsychotic medications have been reported to have beneficial effects on cognitive functioning in patients with schizophrenia. However, these effects have been assessed in studies with considerable variation in methodology. A large number of investigator-initiated and industry-sponsored clinical trials are currently underway to determine the effect of various novel antipsychotics on cognitive deficits in patients […]

Read More

Test-retest reliability of the Dot Test of Visuospatial Working Memory in patients with schizophrenia and controls

by Brittany Scaturro | September 29, 2000 | Publications and Articles

To determine the test-retest reliability of the Dot Test of Visuospatial Working Memory, this task was administered to 29 patients with schizophrenia and 19 normal controls on two consecutive days. The test involved “copying” trials followed by “delay” recall trials. For “copying” trials, subjects saw a dot and then drew it on a blank sheet […]

Read More

Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia

by Brittany Scaturro | August 29, 1997 | Publications and Articles

Thirty patients with a DSM-III-R diagnosis of schizophrenia were assessed for severity of schizophrenic symptoms using the Brief Psychiatric Rating Scale (BPRS) and were tested on a Continuous Performance Test (CPT) and a smooth pursuit eye tracking task. Negative symptoms were significantly correlated with eye tracking impairment (r = 0.43, p < 0.01) and CPT […]

Read More

Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay

by Brittany Scaturro | July 25, 1997 | Publications and Articles

Human and nonhuman primate data suggest that visuospatial working memory is mediated by a neural network that includes the prefrontal cortex. Simple working memory tasks are less complex than standard neuropsychological tests of frontal dysfunction. As such, they are less vulnerable to general performance factors such as amotivation and uncooperativeness in schizophrenic patients. These tasks […]

Read More

Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia

by Brittany Scaturro | February 2, 1997 | Publications and Articles

Biological relatives of patients with schizophrenia demonstrate an increased prevalence of schizotypal personality disorder symptoms, eye tracking deficits, and attentional disturbances. We investigated whether these hypothesized components of a schizophrenia-related phenotype are associated with one another or are independent in nonpsychotic relatives of patients with schizophrenia. Keefe RSE, Silverman J, Mohs RC, Siever LJ, Harvey […]

Read More

Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale

by Brittany Scaturro | October 15, 1996 | Publications and Articles

There has been little investigation of the effect of neuroleptic medication on the structure of symptoms in schizophrenia. In this study, 135 male schizophrenic patients were rated with the Brief Psychiatric Rating Scale (BPRS) after 4 weeks of treatment with typical neuroleptic medication and after 2 weeks free of neuroleptics, with the order of assessment […]

Read More

Clinical characteristics of Kraepelinian schizophrenia: Replication and extension of previous findings

by Brittany Scaturro | June 2, 1996 | Publications and Articles

Subtypologies of schizophrenia based on cross-sectional criteria, such as the nomenclature of the DSMs, have not been successful in identifying valid diagnostic subgroups among patients with schizophrenia. A subtypology that uses criteria to classify individuals on the basis of longitudinal deficits in self-care may identify a more valid subgroup of schizophrenic patients. Keefe RSE, Frecska […]

Read More

Severity of symptoms in chronically institutionalized geriatric schizophrenic patients

by Brittany Scaturro | February 28, 1995 | Publications and Articles

The goal of this study was to characterize the symptoms of geriatric, chronically ill, institutionalized schizophrenic patients and investigate age-related differences in schizophrenic symptoms and cognitive performance from early adulthood to late senescence. Davidson M, Harvey PD, Powchik P, Parrella M, White L, Knobler HY, Losonczy MF, Keefe RSE, Katz S, Frecska E. Severity of […]

Read More

Learning and memory in combat veterans with post-traumatic stress disorder

by Brittany Scaturro | January 30, 1995 | Publications and Articles

The authors investigated a broad range of memory functions for stimuli unrelated to trauma to determine whether symptoms such as intrusive memories might reflect an underlying cognitive deficit unrelated to the psychological content of the traumatic memory in patients with posttraumatic stress disorder (PTSD). Yehuda R, Keefe RSE, Harvey PD, Levengood RA, Gerber DK, Geni […]

Read More

The contribution of neuropsychology to psychiatry

by Brittany Scaturro | January 6, 1995 | Publications and Articles

Neuropsychological test data are applied with increasing frequency in research studies and clinical practice in psychiatry. This article addresses three popular assumptions about neuropsychological test data and describes the limitations and contributions of neuropsychological assessment of patients with psychiatric disorders. Keefe RSE. The contribution of neuropsychology to psychiatry. American Journal of Psychiatry, 1995; 152 (1): […]

Read More

Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms

by Brittany Scaturro | November 30, 1992 | Publications and Articles

The factor structure of the Scale for the Assessment of Negative Symptoms (SANS) was examined in a confirmatory factor analysis that used the LISREL procedure. Four models of negative symptom factors were tested in 130 hospitalized schizophrenic patients. A three-factor model of diminished expression, social dysfunction, and disorganization generated by the authors yielded a superior […]

Read More

A study of the reliability of the family history method in genetic studies of Alzheimer disease

by Brittany Scaturro | December 29, 1989 | Publications and Articles

The reliability between 2 raters conducting independent family history interviews for Alzheimer disease-like and other dementias was investigated. The interviews were conducted at least 1 year apart with the second rater blind to the data collected by the first rater. Raters agreed on the presence and type of dementia in 153 relatives age 45 or […]

Read More

Premorbid sociosexual functioning and long-term outcome in schizophrenia

by Brittany Scaturro | February 28, 1989 | Publications and Articles

Chronic schizophrenic patients with the most severe social deterioration have been shown to differ from other chronic schizophrenic patients with respect to measures of left-to-right ventricular asymmetry, negative symptoms, and response to haloperidol treatment. In the current study, the authors investigated the social antecedents of these characteristics of very poor outcome schizophrenia in 69 chronic […]

Read More

Characteristics of very poor outcome schizophrenia

by Brittany Scaturro | July 29, 1987 | Publications and Articles

The authors compared 21 “Kraepelinian” schizophrenic patients who had been ill and dependent on others for the past 5 years with 76 chronic schizophrenic patients in remission or with exacerbations requiring hospitalization. The Kraepelinian patients met the criteria for schizophrenia by more diagnostic systems than the exacerbated patients, were less responsive to haloperidol, had more […]

Read More

    Magnitude and Predictors of MATRICS Consensus Cognitive Battery Change in Placebo Treated Patients with Schizophrenia

    by Brittany Scaturro | May 14, 2015 | Presentation

    Society of Biological Psychiatry’s 70th Annual Meeting Toronto, May 14-16 2015 View Poster

    Read More

    Validation of a computerized assessment of functional capacity

    by Brittany Scaturro | March 28, 2015 | Presentation

    15th International Congress on Schizophrenia Research Colorado Spring, March 28-April 1 2015 View Poster

    Read More

      A computerized, self-administered test of verbal episodic memory in elderly patients with mild cognitive impairment and healthy participants: A randomized, crossover, validation study

      by Sydney Araya | November 19, 2018 | Publications and Articles

      A computerized, self-administered test of verbal episodic memory in elderly patients with mild cognitive impairment and healthy participants: A randomized, crossover, validation study Randall L. Morrison, Huiling Pei, Gerald Novak, Daniel I. Kaufer, Kathleen A. Welsh-Bohmer, Stephen Ruhmel, Vaibhav A. Narayan Abstract: Introduction: Performance of “Revere”, a novel iPad-administered word-list recall (WLR) test, in quantifying […]

      Read More

      Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency)

      by Sydney Araya | November 5, 2018 | Publications and Articles

      If you were at all connected to the popular media in the early part of this decade, you may recall seeing regular advertisements about the computerized brain training product Lumosity. The claims made in those ads boiled the blood of many clinical researchers and neuroscientists who were engaged in painstakingly testing the efficacy of various […]

      Read More

      TOMMORROW neuropsychological battery: German language validation and normative study

      by Ashley Davis | October 19, 2018 | Publications and Articles

      Read More

      Pioneering Prodromal Science – The Evolution of Prediction & Prevention in Psychotic Disorders

      by Rich Keefe, PhD. | November 29, 2017 | Publications and Articles

      by Rich Keefe, Ph.D. When physicians interviewed patients hospitalized after their initial psychotic episode, they were startled to learn that in many cases, “people began experiencing changes in cognition, behavior, and perception for months or years before psychosis struck,” says Dr. Robert Heinssen of the National Institute of Mental Health in the recent Science article, A […]

      Read More

      NCT Linguistics’ Parent Company, NeuroCog Trials, Announces the Addition of Dr. Luca Pani – Press Release

      by Brittany Pelegrino | September 18, 2017 | Publications and Articles

      DURHAM, NORTH CAROLINA, September 18, 2017 NeuroCog Trials (NCT), a clinical technology and research services company dedicated to supporting global drug development, announces the addition of former AIFA Director General, Dr. Luca Pani, as Executive Director of Global Medical Innovation. Dr. Pani will guide the company’s development of innovative solutions for clinical trials methodologies and […]

      Read More

      Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction

      by James Riley | July 27, 2017 | Publications and Articles

      Individuals at clinical high risk (CHR) often present with a mixture of dif culties in addition to subthreshold psychotic symptoms, such as neurocognitive decline, premorbid dysfunction, and anxious/mood disorders.1–4 Heterogeneity impedes research by obscuring potentially discrete subtypes, which hinders clinical research, evalua- tion, and treatment.

      Read More

      NEUROCOG TRIALS INTRODUCES NCT PATHWAY: NEXT GENERATION eCOA FOR CLINICAL TRIALS – PRESS RELEASE

      by Brittany Scaturro | July 13, 2017 | Publications and Articles

      Innovative platform designed to deliver the highest quality of clinical data, streamline site processes, and improve patient experience   DURHAM, NORTH CAROLINA, JULY 13, 2017 – NeuroCog Trials (NCT), a clinical technology and research services company dedicated to supporting global drug development, announces the general availability of its new flagship eCOA platform, NCT Pathway. Developed […]

      Read More

      Placebo Response and Practice Effects in Schizophrenia Cognition Trials

      by Brittany Scaturro | July 11, 2017 | Publications and Articles

      Questions:  What is the magnitude of learning effects in patients with schizophrenia receiving placebo on the criterion standard Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB), and can these learning effects be anticipated in individual patients?

      Read More

      Cognitive burden of anticholinergic medications in psychotic disorders

      by Brittany Scaturro | April 13, 2017 | Publications and Articles

      Patients with psychotic disorders are often treated with numerous medications, many of which have anticholinergic activity. We assessed cognition in relation to the cumulative anticholinergic burden of multiple drugs included in treatment regimens of participants from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study.

      Read More

      Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia

      by Brittany Scaturro | March 28, 2017 | Publications and Articles

      Article in JAMA Psychiatry One of the greatest challenges for the identification of the causes and cures for schizophrenia is the overwhelming heterogeneity of the disorder. Schizophrenia is defined by symptoms that have only weak associations with one another and are found in patients with other illnesses. Further, some of the most devastating symptoms, such […]

      Read More

      Validation of the Persian version of the Schizophrenia Cognition Rating Scale (SCoRS) in patients with schizophrenia

      by Brittany Scaturro | February 28, 2017 | Publications and Articles

      The Schizophrenia Cognition Rating Scale (SCoRS) is an interview-based assessment of cognition that involves interviews with patients and informants. The SCoRS has shown good reliability, validity, and sensitivity to cognitive impairment in schizophrenia, with the advantage of brief administration and scoring time. The present study aimed to test the concurrent validity of the Persian version […]

      Read More

      Innovative Technologies Expedite Cognition Drug Development – Article

      by Brittany Scaturro | January 3, 2017 | Publications and Articles

      NeuroCog Trials develops innovative technologies that use virtual reality and computerized assessments to augment the measurement of cognitive and functional abilities in clinical trials. Both the VRFCAT – Virtual Reality Functional Capacity Assessment Tool and BAC App – Brief Assessment of Cognition App were recently highlighted in the Research Features Magazine. Find a link to […]

      Read More

      Validation of the tablet-administered Brief Assessment of Cognition (BAC App)

      by Brittany Scaturro | November 1, 2016 | Publications and Articles

      The validation study of our proprietary Brief Assessment of Cognition (BAC App) is now in press in Schizophrenia Research, available as Open Access PDF.

      Read More

      IOM Neuroscience Trials of the Future (Second Update)

      by Brittany Scaturro | September 8, 2016 | Publications and Articles

      UPDATE SEPTEMBER 8, 2016: The prepublication of  Neuroscience Trials of the Future: Proceedings of a Workshop is now available online at the National Academies Press. UPDATE APRIL 5, 2016: Presentations are now available for review at Neuroscience Trials of the Future: A Workshop (Click on Presentations at top right) Institute of Medicine (IOM), Washington, DC, 3-4th […]

      Read More

      NeuroCog Trials Receives $2 Million Grant from the National Institute of Mental Health – Press Release

      by Brittany Scaturro | August 11, 2016 | Publications and Articles

      NIH Grant Will Support the Collection of US Census-Matched Norms and Internationalization of the Virtual Reality Functional Capacity Assessment Tool, VRFCAT™.   DURHAM, NORTH CAROLINA, August 11, 2016 – NeuroCog Trials, Inc., the leading cognitive services provider for the clinical trials industry, today announced that it has been awarded a Phase IIB grant from the […]

      Read More

      Implementing Neurocognitive Testing in Clinical Trials: Facilitating Rater Administration with an iPad-based App

      by Brittany Scaturro | July 5, 2016 | Publications and Articles

      To facilitate rater administration of neurocognitive testing in clinical trials, we developed an iPad-based application (BAC App) of a widely used pen-and-paper battery, the Brief Assessment of Cognition (BAC). The purpose of the BAC App is to reduce administration burden on site raters by automating and standardizing the testing procedures and scoring, while maintaining the […]

      Read More

      NeuroCog Trials Receives $1.4MM Grant From The National Institute On Aging

      by Brittany Scaturro | May 19, 2016 | Publications and Articles

      NIH Funding Will Support Further Development Of The BAC App For Use As A Screening Tool For Cognitive Decline In Aging Populations   DURHAM, NORTH CAROLINA, May 18, 2016 – NeuroCog Trials, Inc., the leading cognitive services provider for the clinical trials industry, today announced that it has been awarded a 2016 Direct to Phase II […]

      Read More

      Validation of The Virtual Reality Functional Capacity Assessment Tool (VRFCAT) is published

      by Brittany Scaturro | May 5, 2016 | Publications and Articles

      The validation study of NeuroCog Trials’ Virtual Reality Functional Capacity Assessment Tool (VRFCAT) is now in press in Schizophrenia Research, available as Open Access. Performance on the VRFCAT was compared to the MATRICS Consensus Cognitive Battery (MCCB) and the UCSD Performance-based Skills Assessment (UPSA) in 167 patients with schizophrenia, and 166 healthy controls, at 3 […]

      Read More

      The BACS and near-infrared spectroscopy (NIRS) as a biomarker in schizophrenia drug trials

      by Brittany Scaturro | February 22, 2016 | Publications and Articles

      A new study published in Schizophrenia Research used the Brief Assessment of Cognition in Schizophrenia (BACS) to investigate the correlation between cognitive function and brain activity in the frontal and temporal lobes, measured with NIRS during a memory task. The study was conducted at Tottori University Hospital in Japan, using the Japanese language version of […]

      Read More

      The genetic association of synaptic protein variants with cognition in schizophrenia, using the BACS

      by Brittany Scaturro | February 16, 2016 | Publications and Articles

      The study of 342 patients with schizophrenia showed significant effects of the adducin ADD2 polymorphisms, with CC genotype carriers performing better on almost all cognitive domains assessed by the Brief Assessment of Cognition in Schizophrenia (BACS).

      Read More

      NeuroCog Trials launches language division for complex translations

      by Brittany Scaturro | January 19, 2016 | Publications and Articles

            PRESS RELEASE Durham, January 19, 2016– NeuroCog Trials is excited to announce a new division, NCT Linguistics, a language service provider focused on the life sciences industry and the global need for precision translations.

      Read More

      Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia

      by Brittany Scaturro | January 8, 2016 | Publications and Articles

      If treatments for cognitive impairment are to be utilized successfully, clinicians must be able to determine whether they are effective and which patients should receive them.

      Read More

      Cognitive Impairment in Schizophrenia and Poor Functional Outcomes: Understanding the Research and Patients’ Real-World Experiences

      by Brittany Scaturro | January 5, 2016 | Publications and Articles

      Developed in conjunction with a panel of experts in the field of schizophrenia, this eBook aims to provide an overview of a core, yet often overlooked, feature of schizophrenia: cognitive impairment. Cognitive impairment in schizophrenia is associated with poor functional outcomes. To help you better understand this condition, the expert clinicians featured in the eBook […]

      Read More

      NIMH study uses the Brief Assessment of Cognition with NeuroCog Trials support to find that cognitive outcomes are stronger than diagnosis in parsing psychosis subgroups

      by Brittany Scaturro | December 9, 2015 | Publications and Articles

      A new NIMH-funded study shows that biological factors better classify psychosis than observable symptoms. This supports NIMH’s Research Diagnostic Criteria (RDoC) initiative, which frees scientists from designing research based on traditional diagnostic categories,

      Read More

      Circumstances under which practice does not make perfect: A review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies

      by Brittany Scaturro | November 18, 2015 | Publications and Articles

      In this article, we review the literature on practice effects in schizophrenia, an underappreciated confound in interpreting cognitive improvement in clinical trials. We first examine claims regarding first- and second-generation antipsychotic medications as cognitive enhancers, and follow it with a discussion of recent studies demonstrating how practice or placebo effects may drive ‘positive’ findings. Thus, […]

      Read More

      Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia)

      by Brittany Scaturro | November 5, 2015 | Publications and Articles

      The Brief Assessment of Cognition in Schizophrenia was administered to 116 stable patients with schizophrenia and 58 matched control subjects. To assess concurrent validity, a subset of patients underwent a traditional neuropsychological assessment. Araujo GE, Resende CB, Cardoso AC, Teixeira AL, Keefe RS, Salgado JV. Validity and reliability of the Brazilian Portuguese version of the […]

      Read More

      Lifetime comorbidity, lifetime history of psychosis and suicide attempts, and current symptoms of patients with deteriorated affective disorder

      by Brittany Scaturro | November 2, 2015 | Publications and Articles

      This study extends our prior research by examining the lifetime comorbidity, history of psychosis and suicide attempts, and current symptoms of an unusual group of patients with major affective disorders who have not only been symptomatic for prolonged periods but have also been so functionally impaired that they required years of care in psychiatric facilities […]

      Read More

      Assessment of age-related differences in functional capacity using the Virtual Reality Functional Assessment Tool (VRFCAT)

      by Brittany Scaturro | October 5, 2015 | Publications and Articles

      Clinical trials for primary prevention and early intervention in preclinical AD require measures of functional capacity with improved sensitivity to deficits in healthier, non-demented individuals. To this end, the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) was developed as a direct performance-based assessment of functional capacity that is sensitive to changes in function across multiple […]

      Read More

      Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first episode schizophrenia.

      by Brittany Scaturro | October 5, 2015 | Publications and Articles

      Deficient vitamin D levels are very common among Americans of all ages and ethnicities, but little is known about its prevalence or associated problems among those with schizophrenia. Early Interv Psychiatry. 2015 Oct;9(5):397-405. doi: 10.1111/eip.12122. Epub 2014 Feb 24.  

      Read More

      Cognitive Disturbances in Major Depression: What Are We Missing?

      by Pierre Roux | September 24, 2015 | Publications and Articles

      Dr. Keefe recently presented new major findings on major depression. Follow the link below and follow the instructions at the bottom of each page to view the video. View Full Article

      Read More

      Latent structure of cognition in schizophrenia: A confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB)

      by Brittany Scaturro | September 5, 2015 | Publications and Articles

      The number of separable cognitive dimensions in schizophrenia has been debated. Guided by the extant factor analytic literature, the NIMH Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative selected seven cognitive domains relevant to treatment studies in schizophrenia: speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, […]

      Read More

      Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extended beyond deficits predicted by generalized neuropsychological impairment

      by Brittany Scaturro | August 5, 2015 | Publications and Articles

      Working memory impairment is well established in psychotic disorders. However, the relative magnitude, diagnostic specificity, familiality pattern, and degree of independence from generalized cognitive deficits across psychotic disorders remain unclear. Hill KS, Buchholz A, Amsbaugh H, Reilly JL, Rubin LH, Gold JM, Keefe RS, Pearlson GD, Keshavan MS, Tamminga CA, Sweeney JA. Working memory impairment […]

      Read More

      A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder.

      by Brittany Scaturro | July 5, 2015 | Publications and Articles

      This multicenter, randomized, double-blind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of vortioxetine (10-20 mg) on cognitive function in adults (aged 18-65 years) diagnosed with major depressive disorder (MDD) who self-reported cognitive dysfunction. Efficacy was evaluated using ANCOVA for the change from baseline to week 8 in the digit […]

      Read More

      Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia

      by Brittany Scaturro | June 19, 2015 | Publications and Articles

      Encenicline is a novel, selective α7 nicotinic acetylcholine receptor agonist in development for treating cognitive impairment in schizophrenia and Alzheimer’s disease. A phase 2, double-blind, randomized, placebo-controlled, parallel-design, multinational study was conducted. Patients with schizophrenia on chronic stable atypical antipsychotics were randomized to encenicline 0.27 or 0.9 mg once daily or placebo for 12 weeks. The […]

      Read More

      Effects of glutamate positive modulators on cognitive deficts in schizophrenia: A systematic review and meta-analysis of double-blind randomized controlled trials

      by Brittany Scaturro | June 16, 2015 | Publications and Articles

      Hypofunction of N-methyl-d-aspartate (NMDA) receptors has been proposed to have an important role in the cognitive impairments observed in schizophrenia. Although glutamate modulators may be effective in reversing such difficult-to-treat conditions, the results of individual studies thus far have been inconsistent. We conducted a systematic review and meta-analysis to examine whether glutamate positive modulators have […]

      Read More

      Phase 2 trial of an Alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia

      by Brittany Scaturro | June 12, 2015 | Publications and Articles

      This trial was conducted to test the effects of an alpha7 nicotinic receptor full agonist, TC-5619, on negative and cognitive symptoms in subjects with schizophrenia. Walling D, Marder SR, Kane J, Fleischhacker WW, Keefe RS, Hosford DA, Dvergsten C, Segreti AC, Beaver JS, Toler SM, Jett JE, Dunbar GC. Phase 2 trial of an Alpha-7 […]

      Read More

      A phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

      by Brittany Scaturro | May 5, 2015 | Publications and Articles

      This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H₃ receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7 weeks (4 weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite […]

      Read More

      Reduced white matter integrity and verbal fluency impairment in young adults with bipolar disorder: a diffusion tensor imaging study

      by Brittany Scaturro | March 5, 2015 | Publications and Articles

      Clinical evidence shows that bipolar disorder (BD) is characterized by white matter (WM) microstructural abnormalities. However, little is known about the biological mechanisms associated with these abnormalities and their relationship with cognitive functioning. Bauer IE, Ouyang A, Mwangi B, Sanches M, Zunta-Soares GB, Keefe RSE, Huang H, Soares JC. Reduced white matter integrity and verbal […]

      Read More

      Observable Social Cognition: A Rating Scale (OSCARS): An interview-based assessment for schizophrenia

      by Brittany Scaturro | February 13, 2015 | Publications and Articles

      Individuals with schizophrenia consistently show impairments in social cognition (SC). SC has become a potential treatment target due to its association with functional outcomes. An alternative method of assessment is to administer an observer-based scale incorporating an informant’s “first hand” impressions in ratings. Healey K, Combs D, Gibson C, Keefe R, Roberts D, Penn D. […]

      Read More

      Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale

      by Brittany Scaturro | February 8, 2015 | Publications and Articles

      Cognitive functioning can be assessed with performance-based assessments such as neuropsychological tests and with interview-based assessments. Both assessment methods have the potential to assess whether treatments for schizophrenia improve clinically relevant aspects of cognitive impairment. Keefe RSE, Davis VG, Spagnola NB, Hilt D, Dgetluck N, Ruse S, Patterson TD, Narasimhan M, Harvey PD. Reliability, validity […]

      Read More

      Resting-state brain function in schizophrenia and psychotic bipolar probands and their first-degree relatives

      by Brittany Scaturro | January 5, 2015 | Publications and Articles

      Schizophrenia (SCZ) and psychotic bipolar disorder (PBD) share considerable overlap in clinical features, genetic risk factors and co-occurrence among relatives. The common and unique functional cerebral deficits in these disorders, and in unaffected relatives, remain to be identified. Lui S, Yao L, Xiao Y, Keedy SK, Reilly JL, Keefe RS, Tamminga CA, Keshavan MS, Pearlson […]

      Read More

      Evaluation of cognitive function in bipolar disorder using the Brief Assessment of Cognition in Affective Disorders (BAC-A).

      by Brittany Scaturro | January 5, 2015 | Publications and Articles

      Although cognitive impairment is a core feature of bipolar disorder (BD) there is no instrument of choice for the assessment of bipolar patients. The aim of this study is to assess cognitive performance using the Brief Assessment of Cognition in Affective Disorders (BAC-A), a comprehensive test battery developed specifically for BD, and determine its suitability […]

      Read More

      Refining the latent structure of neuropsychological performance in schizophrenia

      by Brittany Scaturro | December 5, 2014 | Publications and Articles

      Elucidating the cognitive architecture of schizophrenia promises to advance understanding of the clinical and biological substrates of the illness. Traditional cross-sectional neuropsychological approaches differentiate impaired from normal cognitive abilities but are limited in their ability to determine latent substructure. The current study examined the latent architecture of abnormal cognition in schizophrenia via a systematic approach. […]

      Read More

      Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study

      by Brittany Scaturro | November 9, 2014 | Publications and Articles

      Familial neuropsychological deficits are well established in schizophrenia but remain less well characterized in other psychotic disorders. This study from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) consortium 1) compares cognitive impairment in schizophrenia and bipolar disorder with psychosis, 2) tests a continuum model of cognitive dysfunction in psychotic disorders, 3) reports familiality of cognitive […]

      Read More

      Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit

      by Brittany Scaturro | November 5, 2014 | Publications and Articles

      Difficulty inhibiting context-inappropriate behavior is a common deficit in psychotic disorders. The diagnostic specificity of this impairment, its familiality, and its degree of independence from the generalized cognitive deficit associated with psychotic disorders remain to be clarified. Schizophrenia, schizoaffective and bipolar patients with history of psychosis (n=523), their available first-degree biological relatives (n=656), and healthy […]

      Read More

      Detecting reliable cognitive change in individual patients with the MATRICS Consensus Cognitive Battery

      by Brittany Scaturro | October 5, 2014 | Publications and Articles

      Clinicians often need to evaluate the treatment response of an individual person and to know that observed change is true improvement or worsening beyond usual week-to-week changes. This paper gives clinicians tools to evaluate individual changes on the MATRICS Consensus Cognitive Battery (MCCB). We compare three different approaches: a descriptive analysis of MCCB test-retest performance […]

      Read More

      The MATRICS Consensus Cognitive Battery: What We Know 6 Years Later

      by Pierre Roux | September 21, 2014 | Blog

      Following a competitive application process sponsored by the National Institute of Mental Health (NIMH), the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was launched. After 2 years of large consensus meetings, a five-site psychometric and validation study, complex intellectual property agreements, and an endorsement by NIMH and the U.S. Food and […]

      Read More

      Circadian rhythms in cognitive functioning among patients with schizophrenia

      by Pierre Roux | September 19, 2014 | Publications and Articles

      Impact on signal detection in clinical trials of potential pro-cognitive therapies. Read more.

      Read More

      Development of a Virtual Reality Assessment of Everyday Living Skills

      by Brittany Scaturro | September 16, 2014 | Publications and Articles

      Cognitive impairments affect the majority of patients with schizophrenia and these impairments predict poor long term psychosocial outcomes.  Treatment studies aimed at cognitive impairment in patients with schizophrenia not only require demonstration of improvements on cognitive tests, but also evidence that any cognitive changes lead to clinically meaningful improvements.  Measures of “functional capacity” index the […]

      Read More

      Cognition and motivation as treatment targets in schizophrenia

      by Brittany Scaturro | September 6, 2014 | Publications and Articles

      Motivational deficits and cognitive test performance in schizophrenia. [JAMA Psychiatry. 2014] Keefe RSE. Cognition and motivation as treatment targets in schizophrenia.  JAMA Psychiatry, 2014, 71(9): 987-988.

      Read More

      Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories

      by Brittany Scaturro | September 5, 2014 | Publications and Articles

      Elevated antisaccade error rate, reflecting problems with inhibitory behavioral control, is a promising intermediate phenotype for schizophrenia. Here, we consider whether it marks liability across psychotic disorders via common or different neurophysiological mechanisms and whether it represents a neurocognitive risk indicator apart from the generalized cognitive deficit. Reilly JL, Frankovich K, Hill SK, Gershon E, […]

      Read More

      Regressing to prior response preference after set switching implicates striatal dysfunction across psychotic disorders: Findings from the B-SNIP study

      by Brittany Scaturro | September 5, 2014 | Publications and Articles

      Difficulty switching behavioral response sets is established in psychotic disorders. In rodent models, prefrontal lesions cause difficulty initially switching to new response sets (perseverative errors) while striatal lesions cause difficulty suppressing responses to previous choice preferences (regressive errors). Hill SK, Reilly JL, Ragozzino ME, Rubin LH, Bishop JR, Gur RC, Gershon ES, Tamminga CA, Pearlson […]

      Read More

      Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia

      by Brittany Scaturro | September 5, 2014 | Publications and Articles

      Preclinical and clinical data suggest that pregnenolone may be a promising therapeutic in schizophrenia. Pregnenolone is neuroprotective and enhances learning and memory, myelination, and microtubule polymerization. Treatment with pregnenolone elevates allopregnanolone (a neurosteroid that enhances GABAA receptor responses) and pregnenolone sulfate (a positive NMDA receptor modulator). Pregnenolone could thus potentially mitigate GABA dysregulation and/or NMDA […]

      Read More

      Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review

      by Brittany Scaturro | August 9, 2014 | Publications and Articles

      Cognitive impairment frequently accompanies major depressive disorder (MDD) and can persist during remission. This review examined pharmacotherapy effects on cognitive function in MDD Keefe RSE, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M. Cognitive effects of pharmacotherapy for major depressive disorder:  A systemic review.  Journal of Clinical Psychiatry, 2014; 75(8): 864-876.

      Read More

      Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies

      by Brittany Scaturro | August 6, 2014 | Publications and Articles

      Cognition is affected by circadian rhythms over the course of a day. Circadian rhythms in cognitive functioning are driven by a variety of both endogenous and exogenous factors. Patients with schizophrenia are known to have disturbed circadian rhythms that can affect their cognitive functioning. Hufford MR, Davis VG, Hilt D, Dgetluck N, Geffen Y, Loebel A, […]

      Read More

      Brief assessment of cognition in schizophrenia: normative data in an English-speaking ethnic Chinese sample

      by Brittany Scaturro | August 1, 2014 | Publications and Articles

      There is a dearth of non-Western normative data for neuropsychological batteries designed to measure cognitive deficits in schizophrenia. Here, we provide normative data for English-speaking ethnic Chinese on the widely used Brief Assessment of Cognition in Schizophrenia acquired from 595 healthy community participants between ages 14 and 55. Means and standard deviations of subtests and […]

      Read More

      Virtual Reality Functional Capacity Assessment In Schizophrenia: Preliminary data regarding diagnostic differences and correlations with cognitive performance.

      by Brittany Scaturro | July 5, 2014 | Publications and Articles

      Assessment of functional capacity is an intrinsic part of determining the functional relevance of response to treatment of cognitive impairment in schizophrenia. Existing methods are highly and consistently correlated with performance on neuropsychological tests, but most current assessments of functional capacity are still paper and pencil simulations. We developed a computerized virtual reality assessment that […]

      Read More

      Cognitive Deficits in Bipolar Depression Measured With the Brief Assessment of Cognition in Affective Disorders (BAC-A)

      by Brittany Scaturro | May 11, 2014 | Publications and Articles

      Cognitive deficits in bipolar disorder are significant enough to impact everyday functioning. A key question for treatments aimed at cognition is which cognitive domains are most affected by bipolar disorder and which cognitive tests have the best psychometric characteristics for this population. Keefe RS, Fox KH, Davis VG, Kennel C, Walker TM, Burdick KE, Harvey […]

      Read More

      Development of a virtual reality assessment of everyday living skills

      by Brittany Scaturro | April 23, 2014 | Publications and Articles

      Cognitive impairments affect the majority of patients with schizophrenia and these impairments predict poor long term psychosocial outcomes.  Treatment studies aimed at cognitive impairment in patients with schizophrenia not only require demonstration of improvements on cognitive tests, but also evidence that any cognitive changes lead to clinically meaningful improvements. Ruse SA, Davis VG, Atkins AS, […]

      Read More

      Virtual reality functional capacity assessment in schizophrenia: Preliminary data regarding feasibility and correlations with cognitive and functional capacity performance

      by Brittany Scaturro | March 12, 2014 | Publications and Articles

      Assessment of functional capacity is an intrinsic part of determining the functional relevance of response to treatment of cognitive impairment in schizophrenia. Existing methods are highly and consistently correlated with performance on neuropsychological tests, but most current assessments of functional capacity are still paper and pencil simulations. We developed a computerized virtual reality assessment that […]

      Read More

      A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia

      by Brittany Scaturro | January 27, 2014 | Publications and Articles

      Effective treatments for cognitive impairment associated with schizophrenia (CIAS) remain an unmet need. Nicotinic α7 receptor agonists may be effective in CIAS. This 8-week (week 1, inpatient; weeks 2-8, outpatient), double-blind, randomized study used Measurement And Treatment Research to Improve Cognition in Schizophrenia (MATRICS) guidelines to investigate the nicotinic α7 partial agonist RG3487 (formerly MEM3454) […]

      Read More

      Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study

      by Brittany Scaturro | January 9, 2014 | Publications and Articles

      Despite the widespread belief that neuropsychological decline is a cardinal feature of the progression from the premorbid stage to the chronic form of schizophrenia, few longitudinal studies have examined change in neuropsychological functioning from before to after illness onset. The authors examined whether neuropsychological decline is unique to schizophrenia, whether it is generalized or confined […]

      Read More

      Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia

      by Brittany Scaturro | November 5, 2013 | Publications and Articles

      A number of pharmacological agents for treating negative symptoms in schizophrenia are currently in development. Unresolved questions regarding the design of clinical trials in this area were discussed at an international meeting in Florence, Italy in April 2012. Participants included representatives from academia, the pharmaceutical industry, and the European Medicines Agency (EMA). Marder SR, Alphs […]

      Read More

      Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls

      by Brittany Scaturro | October 31, 2013 | Publications and Articles

      The Brief Assessment of Cognition in Schizophrenia (BACS) is designed for assessment of cognitive function in patients with schizophrenia. Versions of the BACS in English and other languages have been shown to be as sensitive to cognitive dysfunction as a standard test battery, with the advantage of brief administration and scoring time. The present study […]

      Read More

      Schizophrenia is a cognitive illness: time for a change in focus

      by Brittany Scaturro | October 9, 2013 | Publications and Articles

      Schizophrenia is currently classified as a psychotic disorder. This article posits that this emphasis on psychosis is a conceptual fallacy that has greatly contributed to the lack of progress in our understanding of this illness and hence has hampered the development of adequate treatments. Not only have cognitive and intellectual underperformance consistently been shown to […]

      Read More

      Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials

      by Brittany Scaturro | May 10, 2013 | Publications and Articles

      This article captures the proceedings of a meeting aimed at defining clinically meaningful effects for use in randomized controlled trials for psychopharmacological agents. Keefe RS, Kraemer HC, Epstein RS, Frank E, Haynes G, Laughren TP, McNulty J, Reed SD, Sanchez J, Leon AC. Defining a clinically meaningful effect for the design and interpretation of randomized […]

      Read More

      How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS

      by Brittany Scaturro | May 5, 2013 | Publications and Articles

      Interview-based scales can be used as coprimary measures to complement the assessment of cognitive impairment in schizophrenia. One major question that arises from the use of such tools is how specific they are in relation to other psychopathological domains. We analyse the specificity of the Positive and Negative Syndrome Scale (PANSS) negative subscale and the […]

      Read More

      The Cognitive Assessment Interview (CAI): Reliability and validity of a brief interview-based measure of cognition

      by Brittany Scaturro | May 5, 2013 | Publications and Articles

      To obtain Food and Drug Administration approval for the treatment of cognitive impairments associated with schizophrenia, a drug will need to demonstrate benefits beyond those that may be documented on objective cognitive tests. Interview-based measures of cognition such as the Cognitive Assessment Interview (CAI) are candidate coprimary outcome measures. Ventura J, Reise SP, Keefe RSE, […]

      Read More

      The course of cognitive functioning over six months in individuals at clinical high risk for psychosis

      by Brittany Scaturro | April 30, 2013 | Publications and Articles

      Cognitive impairment is common in psychosis and has recently been observed in individuals at clinical high risk (CHR) of developing psychosis. The purpose of this study was to characterize longitudinal change in cognition among CHR individuals, and compare cognition of CHR individuals who later convert to psychosis to that of CHR who do not convert. […]

      Read More

      Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care

      by Brittany Scaturro | March 17, 2013 | Publications and Articles

      The Schizophrenia Cognition Rating Scale (SCoRS), an interview-based assessment of cognition, has proved to be a valid measure of cognitive performance in patients with schizophrenia. Vita A, Deste G, Barlati S, De Peri L, Giambra A, Poli R, Keefe RSE, Sacchetti E. Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) […]

      Read More

      Clinical trials of potential cognitive-enhancing drugs in schizophrenia: What have we learned so far?

      by Brittany Scaturro | March 5, 2013 | Publications and Articles

      In light of the number of studies conducted to examine the treatment of cognitive impairment associated with schizophrenia (CIAS), we critically reviewed recent CIAS trials. Trials were identified through searches of the website “www.clinicaltrials.gov” using the terms “schizophrenia AND cognition,” “schizophrenia AND neurocognition,” “schizophrenia AND neurocognitive tests,” “schizophrenia AND MATRICS,” “schizophrenia AND MCCB,” “schizophrenia AND […]

      Read More

      Applicability of the MATRICS Consensus Cognitive Battery in Singapore

      by Brittany Scaturro | January 30, 2013 | Publications and Articles

      The MATRICS Consensus Cognitive Battery (MCCB) was developed to provide a reliable, valid, and standard battery for clinical trials on cognitive enhancers in schizophrenia. In this study we tested the applicability of the MCCB to Singapore’s English speakers. Healthy ethnic Chinese, Malay, and Indian English speakers (N = 171) of both genders were recruited within […]

      Read More

      Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: A 13-week, randomized, placebo-controlled, crossover trial

      by Brittany Scaturro | January 1, 2013 | Publications and Articles

      Patients were randomly assigned to receive milnacipran or placebo for 6 weeks, followed by a 1-week washout and then crossover to the other arm for another 6 weeks. The overall trial lasted 13 weeks and was conducted between July 2011 and May 2013. Assessments were performed at each visit. Kim JL, Rele S, Marks DM, […]

      Read More

      Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia

      by Brittany Scaturro | December 20, 2012 | Publications and Articles

      The Reasons for Antipsychotic Discontinuation Questionnaire (RAD-Q) was designed to assess clinicians’ perceptions of reasons for antipsychotic discontinuation or continuation. The current study examined psychometric properties of this instrument and patterns of antipsychotic discontinuation. The sample of 121 patients (81 discontinuation, 40 continuation) with schizophrenia or schizoaffective disorder was 66.9% male, with a mean age […]

      Read More

      Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study

      by Brittany Scaturro | December 5, 2012 | Publications and Articles

      The Continuous Performance Test (CPT) has emerged as the most commonly administered measure of sustained attention, but use of discrepant versions reduces the ability of researchers and clinicians to accurately draw cross-study conclusions. In an effort to standardize use of the CPT, this study compared four versions of the Identical Pairs CPT for their reliability […]

      Read More

      Circadian Rhythms and Cognition: Using Time of Day Effects To Enhance Signal Detection in Clinical Trials of Pro-Cognitive Therapies for Schizophrenia

      by Brittany Scaturro | September 24, 2012 | Publications and Articles

      Circadian Rhythms and Cognition: Using Time of Day Effects To Enhance Signal Detection in Clinical Trials of Pro-Cognitive Therapies for Schizophrenia. M Hufford, V Davis, N Dgetluck, M Gawryl, D Hilt, A Rappaport, R Keefe. Poster presentation at the International Society for CNS Clinical Trials and Methodology 2012 Autumn Conference, October 2012, Los Angeles, CA. […]

      Read More

      Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study

      by Brittany Scaturro | September 13, 2012 | Publications and Articles

      BL-1020 is a γ-aminobutyric acid (GABA)-enhanced antipsychotic that combines dopamine antagonism with GABA agonist activity. On the basis of animal models, we tested the hypotheses that BL-1020 would be effective in ameliorating both psychotic symptoms and cognitive impairments, with a favorable safety profile in acutely ill schizophrenia patients. Geffen Y, Keefe R, Rabinowitz J, Anand […]

      Read More

      Persistent cannabis users show neuropsychological decline from childhood to midlife

      by Brittany Scaturro | July 30, 2012 | Publications and Articles

      Recent reports show that fewer adolescents believe that regular cannabis use is harmful to health. Concomitantly, adolescents are initiating cannabis use at younger ages, and more adolescents are using cannabis on a daily basis. The purpose of the present study was to test the association between persistent cannabis use and neuropsychological decline and determine whether […]

      Read More

      Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial

      by Brittany Scaturro | May 15, 2012 | Publications and Articles

      The true benefit of pharmacologic intervention to improve cognition in schizophrenia may not be evident without regular cognitive enrichment. Clinical trials assessing the neurocognitive effects of new medications may require engagement in cognitive remediation exercises to stimulate the benefit potential. However, the feasibility of large-scale multisite studies using cognitive remediation at clinical trials sites has […]

      Read More

      Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia

      by Brittany Scaturro | April 6, 2012 | Publications and Articles

      Auditory emotion recognition impairments in schizophrenia: relationship to acoustic features and cognition. [Am J Psychiatry. 2012] A new perspective on anhedonia in schizophrenia. [Am J Psychiatry. 2012] Keefe RSE, Kraus MS. Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia.  American Journal of Psychiatry, 2012; 169 (4): 354-357.

      Read More

      Guide to Assessment Scales in Schizophrenia

      by Brittany Scaturro | January 1, 2012 | Publications and Articles

      This book provides a wealth of assessment instruments from the world’s experts to help clinicians gather the most important information from their patients. This is the 3rd edition of our highly successful guides to Rating Scales in Schizophrenia, it is a practical and quick reference publication for psychiatrists. http://www.springer.com/us/book/9781908517524

      Read More

      Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial

      by Brittany Scaturro | December 31, 2011 | Publications and Articles

      The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Project produced a battery of tests, the MATRICS Consensus Cognitive Battery (MCCB), designed to assess cognitive treatment effects in clinical trials of patients with schizophrenia. In validation studies, the MCCB demonstrated excellent reliability, minimal practice effects and significant correlations with measures of functional capacity. […]

      Read More

      Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia

      by Brittany Scaturro | December 12, 2011 | Publications and Articles

      Cognitive dysfunction is a key predictor of functional disability in schizophrenia. Davunetide (AL-108, NAP) is an intranasally administered peptide currently being developed for treatment of Alzheimer’s disease and related disorders. This study investigates effects of davunetide on cognition in schizophrenia. Javitt DC, Buchanan RW, Keefe RSE, Kern R, McMahon RP, Green MF, Lieberman J, Goff […]

      Read More

      The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: What do we know 5 years later?

      by Brittany Scaturro | November 5, 2011 | Publications and Articles

      The Food and Drug Administration (FDA)-National Institute of Mental Health (NIMH)-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) clinical trial guidelines for cognitive-enhancing drugs in schizophrenia and the MATRICS Consensus Cognitive Battery (MCCB) were designed to facilitate novel compound development in the treatment of cognitive impairments. Buchanan RW, Keefe RSE, Umbricht D, Green […]

      Read More

      Report from the Working Group Conference on multi-site trial design for cognitive remediation in schizophrenia. Schizophrenia Bulletin

      by Brittany Scaturro | September 5, 2011 | Publications and Articles

      The National Institute of Mental Health (NIMH)-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Project and related efforts have stimulated the initiation of several studies of pharmacologic treatments for cognitive impairment in schizophrenia. Cognitive remediation may provide an excellent platform for the provision of new learning opportunities and the acquisition of new skills […]

      Read More

      The MATRICS Consensus Cognitive Battery in Patients with bipolar I disorder

      by Brittany Scaturro | July 5, 2011 | Publications and Articles

      The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was devised to identify a neurocognitive battery to be used in clinical trials targeting cognition in schizophrenia, a process, which resulted in the MATRICS Consensus Cognitive Battery (MCCB). The MCCB has been selected by the United States Food and Drug Administration to be […]

      Read More

      Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD

      by Brittany Scaturro | May 15, 2011 | Publications and Articles

      The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer’s disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study (CATIE-AD). Vigen CLP, Mack WJ, Keefe RSE, Sano M, Sultzer DL, Stroup TS, Dagerman […]

      Read More

      Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone

      by Brittany Scaturro | April 5, 2011 | Publications and Articles

      Improving cognitive functioning in people with schizophrenia is a major treatment goal. In addition, interview-based measures have been developed to supplement performance-based assessments. However, few data are available regarding whether interview-based measures are sensitive to treatment-related changes. Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in […]

      Read More

      Methodological issues in negative symptom trials

      by Brittany Scaturro | March 5, 2011 | Publications and Articles

      Individuals from academia, the pharmaceutical industry, and the US Food and Drug Administration used a workshop format to discuss important methodological issues in the design of trials of pharmacological agents for improving negative symptoms in schizophrenia. Marder SR, Daniel DG, Alphs L, Awad AG, Keefe RSE. Methodological issues in negative symptom trials.  Schizophrenia Bulletin, 2011; […]

      Read More

      Validation of the German Version of the Brief Assessment of Cognition in Schizophrenia (BACS) – Preliminary Results

      by Brittany Scaturro | March 5, 2011 | Publications and Articles

      The German version of the BACS showed high test-retest reliability. Sensitivity and specificity scores demonstrated good ability to differentiate between patients and controls. The study suggests that the German Version of the BACS is a useful scale to evaluate cognitive functioning. Sachs G, Winklbaur B, Jagsch R, Keefe RS. Validation of the German Version of […]

      Read More

      Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia

      by Brittany Scaturro | March 5, 2011 | Publications and Articles

      A psychometric analysis of 2 interview-based measures of cognitive deficits was conducted: the 21-item Clinical Global Impression of Cognition in Schizophrenia (CGI-CogS; Ventura et al., 2008), and the 20-item Schizophrenia Cognition Rating Scale (SCoRS; Keefe et al., 2006), which were administered on 2 occasions to a sample of people with schizophrenia. Traditional psychometrics, bifactor analysis, […]

      Read More

      The MCCB impairment profile for schizophrenia outpatients: Results from the MATRICS psychometric and standardization study

      by Brittany Scaturro | March 5, 2011 | Publications and Articles

      The MATRICS Psychometric and Standardization Study was conducted as a final stage in the development of the MATRICS Consensus Cognitive Battery (MCCB). The study included 176 persons with schizophrenia or schizoaffective disorder and 300 community residents. Data were analyzed to examine the cognitive profile of clinically stable schizophrenia patients on the MCCB. Secondarily, the data […]

      Read More

      Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls

      by Brittany Scaturro | March 5, 2011 | Publications and Articles

      Neurocognitive impairment is a core feature of schizophrenia and is closely associated with functional outcome. The importance of cognitive assessment is broadly accepted today, and an easy-to-use, internationality validated cognitive assessment tool is needed by researchers and in daily clinical practice. Segarra N, Bernardo M, Gutierrez F, Justicia A, Fernandez-Egea E, Allas M, Safont G, […]

      Read More

      A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

      by Brittany Scaturro | March 1, 2011 | Publications and Articles

      In a previous pilot study, MK-0777–a γ-aminobutyric acid (GABA)(A) α2/α3 partial agonist–was reported to improve delayed memory and cognitive measures of prefrontal cortical function in people with schizophrenia. The current study was designed to further examine the efficacy and safety of MK-0777 for the treatment of cognitive impairments in schizophrenia. Buchanan RW, Keefe RS, Lieberman […]

      Read More

      Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia

      by Brittany Scaturro | January 1, 2011 | Publications and Articles

      Cognitive deficits present in almost all patients with schizophrenia, and account for considerable functional disability, but as typically measured in schizophrenia are unrelated to hallucinations and delusions. Keefe RSE, Kraus MS, Krishnan RR. Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia.  Neuropsychopharmacology, 2011; 36(1): 367-380.  (PMCID:  PMC3055500).

      Read More

      Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: A 4-week, double-blind, placebo-controlled study

      by Brittany Scaturro | November 5, 2010 | Publications and Articles

      This 4-week, randomized, double-blind, placebo-controlled, proof-of-concept study was conducted between July and December 2007. Patients had a history of stable schizophrenia (DSM-IV-TR criteria) for ≥ 8 weeks and were treated with oral risperidone, olanzapine, or paliperidone for ≥ 6 weeks at stable doses for ≥ 4 weeks. Kane JM, D’Souza DC, Patkar AA, Youakim JM, […]

      Read More

      Differential effects of emotional information on interference task performance across the life span

      by Brittany Scaturro | September 30, 2010 | Publications and Articles

      While functioning in multiple domains declines with age, emotional regulation appears to remain preserved in older adults. The Emotion Inhibition (Emotional Stroop) Test requires participants to name the ink color in which neutrally and emotionally valenced words are printed. It was employed in the current investigation as a measure of affective regulation in the context […]

      Read More

      The Cognitive Assessment Interview (CAI): Development and validation of an empirically derived, brief interview-based measure of cognition

      by Brittany Scaturro | August 3, 2010 | Publications and Articles

      Practical, reliable “real world” measures of cognition are needed to supplement neurocognitive performance data to evaluate possible efficacy of new drugs targeting cognitive deficits associated with schizophrenia. Because interview-based measures of cognition offer one possible approach, data from the MATRICS initiative (n=176) were used to examine the psychometric properties of the Schizophrenia Cognition Rating Scale […]

      Read More

      The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia

      by Brittany Scaturro | June 30, 2010 | Publications and Articles

      Growing interest in cognitive deficits associated with schizophrenia has led to the need for a clinician-friendly cognitive instrument. The Schizophrenia Cognition Rating Scale (SCoRS), recognized for its brevity and ease of administration, has proven to be a valid and reliable measure of overall cognition in schizophrenia patients. However, there has been no such validation in […]

      Read More

      Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis

      by Brittany Scaturro | June 4, 2010 | Publications and Articles

      Early detection and prospective evaluation of clinical high-risk (CHR) individuals who may develop schizophrenia or other psychotic disorders is critical for predicting psychosis onset and for testing preventive interventions. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, […]

      Read More

      Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis

      by Brittany Scaturro | June 3, 2010 | Publications and Articles

      Early detection and prospective evaluation of clinical high-risk (CHR) individuals who may develop schizophrenia or other psychotic disorders is critical for predicting psychosis onset and for testing preventive interventions. Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, […]

      Read More

      Circumstances under which practice does not make perfect: A review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies

      by Brittany Scaturro | April 4, 2010 | Publications and Articles

      In this article, we review the literature on practice effects in schizophrenia, an underappreciated confound in interpreting cognitive improvement in clinical trials. We first examine claims regarding first- and second-generation antipsychotic medications as cognitive enhancers, and follow it with a discussion of recent studies demonstrating how practice or placebo effects may drive ‘positive’ findings. Thus, […]

      Read More

      Proof-of-Concept Trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

      by Brittany Scaturro | July 3, 2009 | Publications and Articles

      The neurosteroid pregnenolone and its sulfated derivative enhance learning and memory in rodents. Pregnenolone sulfate also positively modulates NMDA receptors and could thus ameliorate hypothesized NMDA receptor hypofunction in schizophrenia. Furthermore, clozapine increases pregnenolone in rodent hippocampus, possibly contributing to its superior efficacy. We therefore investigated adjunctive pregnenolone for cognitive and negative symptoms in patients […]

      Read More

      Cognitive effects of antipsychotics drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST)

      by Brittany Scaturro | June 3, 2009 | Publications and Articles

      Cognitive impairment, manifested as mild to moderate deviations from psychometric norms, is present in many but not all schizophrenia patients. The purpose of the present study was to compare the effect of haloperidol with that of second-generation antipsychotic drugs on the cognitive performance of patients with schizophreniform disorder or first-episode schizophrenia. Davidson M, Galderisi S, […]

      Read More

      Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study.

      by Brittany Scaturro | October 2, 2008 | Publications and Articles

      There is uncertainty regarding the onset timing of the cognitive deficiencies of schizophrenia. We investigated whether conversion to psychosis and/or olanzapine altered the neuropsychological course of subjects within the first-ever double blind medication study of the putative schizophrenia first episode prodrome. Hawkins KA, Keefe RSE, Christensen B, Addington J, Woods SW, Callahan J, Zipursky RB, […]

      Read More

      Relationship of cognition and psychopathology to functional impairment in schizophrenia

      by Brittany Scaturro | August 2, 2008 | Publications and Articles

      This study evaluated the association of neurocognition and symptoms with measures of social and occupational functioning in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Mohamed S, Rosenheck R, Swartz M, Stroup S, Lieberman JA, Keefe RSE. Relationship of cognition and psychopathology to function impairment in schizophrenia.  The American Journal of Psychiatry, 2008; 165(8): 978-987.

      Read More

      Norms and standardization of the Brief Assessment of Cognition in Schizophrenia

      by Brittany Scaturro | July 2, 2008 | Publications and Articles

      According to the recommendations of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Neurocognition Committee, one of the desired characteristics of a cognitive battery for assessing cognition in schizophrenia studies and clinical trials is the availability of normative data. Keefe RSE, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, Hawkins […]

      Read More

      Implementation considerations for multisite clinical trials with cognitive neuroscience tasks

      by Brittany Scaturro | May 20, 2008 | Publications and Articles

      Multisite clinical trials aimed at cognitive enhancement across various neuropsychiatric conditions have employed standard neuropsychological tests as outcome measures. While these tests have enjoyed wide clinical use and have proven reliable and predictive of functional disability, a number of implementation challenges have arisen when these tests are used in clinical trials. Keefe RSE, Harvey PD. […]

      Read More

      Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia

      by Brittany Scaturro | March 14, 2008 | Publications and Articles

      Efficient and reliable assessments of cognitive treatment effects are essential for the comparative evaluation of procognitive effects of pharmacologic therapies. Yet, no studies have addressed the sensitivity and efficiency with which neurocognitive batteries evaluate cognitive abilities before and after treatment. Hill SK, Sweeney JA, Hamer RM, Keefe RSE, Perkins DO, Gu H, McEvoy JP, Lieberman […]

      Read More

      Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study

      by Brittany Scaturro | January 2, 2008 | Publications and Articles

      During the consensus meetings of the National Institute of Mental Health Measurement and Treatment Research to Improve Cognition in Schizophrenia (NIMH-MATRICS) Initiative, the U.S. Food and Drug Administration took the position that a drug for this purpose should show changes on 1) an accepted consensus cognitive performance measure and 2) an additional measure (i.e., a […]

      Read More

      The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity

      by Brittany Scaturro | January 2, 2008 | Publications and Articles

      The lack of an accepted standard for measuring cognitive change in schizophrenia has been a major obstacle to regulatory approval of cognition-enhancing treatments. A primary mandate of the National Institute of Mental Health’s Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was to develop a consensus cognitive battery for clinical trials of […]

      Read More

      The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization

      by Brittany Scaturro | January 2, 2008 | Publications and Articles

      The consensus cognitive battery developed by the National Institute of Mental Health’s (NIMH’s) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative includes 10 independently developed tests that are recommended as the standard battery for clinical trials of cognition-enhancing interventions for schizophrenia. To facilitate interpretation of results from the MATRICS Consensus Cognitive Battery […]

      Read More

      Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials

      by Brittany Scaturro | December 15, 2007 | Publications and Articles

      Lamotrigine previously was found to attenuate ketamine-induced behavioral changes and, in 2 placebo-controlled trials, to improve psychosis when added to antipsychotic medication. We sought to evaluate the potential role of lamotrigine augmentation in schizophrenia patients resistant to atypical antipsychotic medication. Goff DC, Keefe RSE, Citrome L, Davy K, Krystal J, Large C, Volayka J, Webster […]

      Read More

      Brief Assessment of Cognition in Schizophrenia: Validation of the Japanese version

      by Brittany Scaturro | December 2, 2007 | Publications and Articles

      This preliminary study was performed to test the reliability and validity of the Brief Assessment of Cognition in Schizophrenia (BACS) as an assessment tool in a Japanese-language version (BACS-J). The subjects for the present study were 30 outpatients with chronic schizophrenia. Each subject gave written informed consent to participate in the research. Kaneda Y, Sumiyoshi […]

      Read More

      Cognition as an outcome measure in schizophrenia

      by Brittany Scaturro | August 14, 2007 | Publications and Articles

      Cognitive deficits are a core feature of schizophrenia. These deficits are not caused by medication or symptoms, and have a dramatic negative effect on real-world functioning. Kraus MS, Keefe RSE. Cognition as an outcome measure in schizophrenia.  British Journal of Psychiatry, 2007; 50: 46-51.  

      Read More

      Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison

      by Brittany Scaturro | July 14, 2007 | Publications and Articles

      The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis. Keefe RSE, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Lieberman JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis:  A randomized, double-blind 52 week comparison.  The American Journal […]

      Read More

      Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial

      by Brittany Scaturro | July 11, 2007 | Publications and Articles

      Altered expression of central muscarinic and nicotinic acetylcholine receptors in hippocampal and cortical regions may contribute to the cognitive impairment exhibited in patients with schizophrenia. Increasing cholinergic activity through the use of a cholinesterase inhibitor (ChEI) therefore represents a possible strategy for cognitive augmentation in schizophrenia. Keefe RSE, Malhotra AK, Meltzer H, Kane JM, Buchanan […]

      Read More

      Sensitivity and applicability of the Brazilian version of the Brief Assessment of Cognition in Schizophrenia (BACS)

      by Brittany Scaturro | July 2, 2007 | Publications and Articles

      Cognitive assessment in schizophrenia has traditionally used batteries that are long and complex or differ widely in their content. The Brief Assessment of Cognition in Schizophrenia (BACS) has been developed to cover the main cognitive deficits of schizophrenia as well as to be easily and briefly administered, portable, sensitive and reliable. Salgado JV, Carvalhaes CFR, […]

      Read More

      Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial

      by Brittany Scaturro | June 14, 2007 | Publications and Articles

      Neurocognitive impairment in schizophrenia is severe and is an important predictor of functional outcome. The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, […]

      Read More

      How should DSM-V criteria for schizophrenia include cognitive impairment?

      by Brittany Scaturro | June 13, 2007 | Publications and Articles

      Neurocognitive impairment is considered a core component of schizophrenia and is increasingly under investigation as a potential treatment target. On average, cognitive impairment is severe to moderately severe compared with healthy controls, and almost all patients with schizophrenia demonstrate cognitive decrements compared with their expected level if they had not developed the illness. Keefe RSE, […]

      Read More

      A longitudinal study of neurocognitive function in individuals at-risk for psychosis

      by Brittany Scaturro | December 2, 2006 | Publications and Articles

      Clinically defined prodromal diagnostic criteria identify at-risk individuals with a 35-40% likelihood of developing a psychotic disorder within a year. The time course and predictive value of cognitive deficits in the development of psychosis has not been established. Keefe RSE, Perkins DO, Gu H, Zipursky RB, Christensen BK, Lieberman JA. A longitudinal study of neurocognitive […]

      Read More

      Baseline neurocognitive deficits in the CATIE schizophrenia trial

      by Brittany Scaturro | September 15, 2006 | Publications and Articles

      Neurocognition is moderately to severely impaired in patients with schizophrenia. However, the factor structure of the various neurocognitive deficits, the relationship with symptoms and other variables, and the minimum amount of testing required to determine an adequate composite score has not been determined in typical patients with schizophrenia. Keefe RSE, Bilder RM, Harvey PD, Davis […]

      Read More

      The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity

      by Brittany Scaturro | March 2, 2006 | Publications and Articles

      Interview-based measures of cognition may serve as potential coprimary measures in clinical trials of cognitive-enhancing drugs for schizophrenia. However, there is no such valid scale available. Interviews of patients and their clinicians are not valid in that they are unrelated to patients’ levels of cognitive impairment as assessed by cognitive performance tests. This study describes […]

      Read More

      The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome

      by Brittany Scaturro | February 15, 2006 | Publications and Articles

      The Brief Assessment of Cognition in Schizophrenia (BACS) assesses five different domains of cognitive function with six tests, and takes about 30-35 minutes to complete in patients with schizophrenia. Previous work has demonstrated the reliability of this measure, and its sensitivity to the deficits of schizophrenia. However, the relationship of this brief cognitive measure to […]

      Read More

      One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia

      by Brittany Scaturro | January 1, 2006 | Publications and Articles

      Neurocognitive deficits in schizophrenia can reach 1 to 2 standard deviations below healthy controls. The comparative effect of typical and atypical antipsychotic medications on neurocognition is controversial, and based primarily on studies with small samples and large doses of typical comparator medications. The present study assessed neurocognitive efficacy. Keefe RSE, Young CA, Rock SL, Purdon […]

      Read More

      Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

      by Brittany Scaturro | September 22, 2005 | Publications and Articles

      The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe […]

      Read More

      Research with spanish-speaking populations in the United States: lost in the translation. A commentary and a plea

      by Brittany Scaturro | July 2, 2005 | Publications and Articles

      Verbal material used to assess the cognitive abilities of Spanish-speakers in the the United States is frequently of linguistically unacceptable quality. The use of these materials in research settings is thought to pose a serious threat to test validity and hence to the validity of claimed results or conclusions. The authors explain how and why […]

      Read More

      Defining a cognitive function decrement in schizophrenia

      by Brittany Scaturro | March 15, 2005 | Publications and Articles

      Although cognitive impairment is described as a core component of the characterization of schizophrenia, a sizable percentage of patients are classified as unimpaired by traditional definitions of impairment. The purpose of this study was to determine the percentage of patients with schizophrenia meeting criteria for a “cognitive function decrement” defined as a current level of […]

      Read More

      A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia

      by Brittany Scaturro | January 16, 2005 | Publications and Articles

      On April 23, 2004, a joint meeting of the FDA, NIMH, MATRICS investigators, and experts from academia and the pharmaceutical industry was convened to develop guidelines for the design of clinical trials of cognitive-enhancing drugs for neurocognitive impairments in patients with schizophrenia. Buchanan RW, Davis M, Goff D, Green MF, Keefe RSE, Leon A, Nuechterlein […]

      Read More

      Cognitive impairment as a target for pharmacological treatment in schizophrenia

      by Brittany Scaturro | December 6, 2004 | Publications and Articles

      Cognitive impairment has emerged as an important new target in schizophrenia therapeutics in light of evidence that cognitive deficits are critically related to the functional of disability that is characteristic of the illness. Evidence is briefly reviewed supporting the idea that the cognitive impairment in schizophrenia is an attractive target for therapeutic intervention including: (1) […]

      Read More

      Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria

      by Brittany Scaturro | September 1, 2004 | Publications and Articles

      To stimulate the development of new drugs for the cognitive deficits of schizophrenia, the National Institute of Mental Health (NIMH) established the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative. This article presents an overview of decisions from the first MATRICS consensus conference. The goals of the meeting were to 1) identify […]

      Read More

      Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

      by Brittany Scaturro | June 16, 2004 | Publications and Articles

      The effect of antipsychotic medication on neurocognitive function remains controversial, especially since most previous work has compared the effects of novel antipsychotic medications with those of high doses of conventional medications. This study compares the neurocognitive effects of olanzapine and low doses of haloperidol in patients with first-episode psychosis. Keefe RSE, Seidman LJ, Christensen BK, […]

      Read More

      The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery

      by Brittany Scaturro | June 1, 2004 | Publications and Articles

      Studies of neurocognitive function in patients with schizophrenia use widely variable assessment techniques. Clinical trials assessing the cognitive enhancing effect of new medications have used neurocognitive assessment batteries that differed in content, length and administration procedures. The Brief Assessment of Cognition in Schizophrenia (BACS) is a newly developed instrument that assesses the aspects of cognition […]

      Read More

      Neuropsychological status of subjects at high risk for a first episode of psychosis

      by Brittany Scaturro | April 1, 2004 | Publications and Articles

      Thirty-six subjects aged 16 years or older judged at risk for a first episode of psychosis within a North American multi-site study of the schizophrenia prodrome [McGlashan et al., Schizophr. Res. (2003); Miller et al., Schizophr. Res. (2003)] performed at levels intermediate to population norms and data reported for schizophrenia samples on a comprehensive neuropsychological […]

      Read More

      Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

      by Brittany Scaturro | February 15, 2001 | Publications and Articles

      Novel antipsychotic medications have been reported to have beneficial effects on cognitive functioning in patients with schizophrenia. However, these effects have been assessed in studies with considerable variation in methodology. A large number of investigator-initiated and industry-sponsored clinical trials are currently underway to determine the effect of various novel antipsychotics on cognitive deficits in patients […]

      Read More

      Test-retest reliability of the Dot Test of Visuospatial Working Memory in patients with schizophrenia and controls

      by Brittany Scaturro | September 29, 2000 | Publications and Articles

      To determine the test-retest reliability of the Dot Test of Visuospatial Working Memory, this task was administered to 29 patients with schizophrenia and 19 normal controls on two consecutive days. The test involved “copying” trials followed by “delay” recall trials. For “copying” trials, subjects saw a dot and then drew it on a blank sheet […]

      Read More

      Attentional and eye tracking deficits correlate with negative symptoms in schizophrenia

      by Brittany Scaturro | August 29, 1997 | Publications and Articles

      Thirty patients with a DSM-III-R diagnosis of schizophrenia were assessed for severity of schizophrenic symptoms using the Brief Psychiatric Rating Scale (BPRS) and were tested on a Continuous Performance Test (CPT) and a smooth pursuit eye tracking task. Negative symptoms were significantly correlated with eye tracking impairment (r = 0.43, p < 0.01) and CPT […]

      Read More

      Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay

      by Brittany Scaturro | July 25, 1997 | Publications and Articles

      Human and nonhuman primate data suggest that visuospatial working memory is mediated by a neural network that includes the prefrontal cortex. Simple working memory tasks are less complex than standard neuropsychological tests of frontal dysfunction. As such, they are less vulnerable to general performance factors such as amotivation and uncooperativeness in schizophrenic patients. These tasks […]

      Read More

      Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia

      by Brittany Scaturro | February 2, 1997 | Publications and Articles

      Biological relatives of patients with schizophrenia demonstrate an increased prevalence of schizotypal personality disorder symptoms, eye tracking deficits, and attentional disturbances. We investigated whether these hypothesized components of a schizophrenia-related phenotype are associated with one another or are independent in nonpsychotic relatives of patients with schizophrenia. Keefe RSE, Silverman J, Mohs RC, Siever LJ, Harvey […]

      Read More

      Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale

      by Brittany Scaturro | October 15, 1996 | Publications and Articles

      There has been little investigation of the effect of neuroleptic medication on the structure of symptoms in schizophrenia. In this study, 135 male schizophrenic patients were rated with the Brief Psychiatric Rating Scale (BPRS) after 4 weeks of treatment with typical neuroleptic medication and after 2 weeks free of neuroleptics, with the order of assessment […]

      Read More

      Clinical characteristics of Kraepelinian schizophrenia: Replication and extension of previous findings

      by Brittany Scaturro | June 2, 1996 | Publications and Articles

      Subtypologies of schizophrenia based on cross-sectional criteria, such as the nomenclature of the DSMs, have not been successful in identifying valid diagnostic subgroups among patients with schizophrenia. A subtypology that uses criteria to classify individuals on the basis of longitudinal deficits in self-care may identify a more valid subgroup of schizophrenic patients. Keefe RSE, Frecska […]

      Read More

      Severity of symptoms in chronically institutionalized geriatric schizophrenic patients

      by Brittany Scaturro | February 28, 1995 | Publications and Articles

      The goal of this study was to characterize the symptoms of geriatric, chronically ill, institutionalized schizophrenic patients and investigate age-related differences in schizophrenic symptoms and cognitive performance from early adulthood to late senescence. Davidson M, Harvey PD, Powchik P, Parrella M, White L, Knobler HY, Losonczy MF, Keefe RSE, Katz S, Frecska E. Severity of […]

      Read More

      Learning and memory in combat veterans with post-traumatic stress disorder

      by Brittany Scaturro | January 30, 1995 | Publications and Articles

      The authors investigated a broad range of memory functions for stimuli unrelated to trauma to determine whether symptoms such as intrusive memories might reflect an underlying cognitive deficit unrelated to the psychological content of the traumatic memory in patients with posttraumatic stress disorder (PTSD). Yehuda R, Keefe RSE, Harvey PD, Levengood RA, Gerber DK, Geni […]

      Read More

      The contribution of neuropsychology to psychiatry

      by Brittany Scaturro | January 6, 1995 | Publications and Articles

      Neuropsychological test data are applied with increasing frequency in research studies and clinical practice in psychiatry. This article addresses three popular assumptions about neuropsychological test data and describes the limitations and contributions of neuropsychological assessment of patients with psychiatric disorders. Keefe RSE. The contribution of neuropsychology to psychiatry. American Journal of Psychiatry, 1995; 152 (1): […]

      Read More

      Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms

      by Brittany Scaturro | November 30, 1992 | Publications and Articles

      The factor structure of the Scale for the Assessment of Negative Symptoms (SANS) was examined in a confirmatory factor analysis that used the LISREL procedure. Four models of negative symptom factors were tested in 130 hospitalized schizophrenic patients. A three-factor model of diminished expression, social dysfunction, and disorganization generated by the authors yielded a superior […]

      Read More

      A study of the reliability of the family history method in genetic studies of Alzheimer disease

      by Brittany Scaturro | December 29, 1989 | Publications and Articles

      The reliability between 2 raters conducting independent family history interviews for Alzheimer disease-like and other dementias was investigated. The interviews were conducted at least 1 year apart with the second rater blind to the data collected by the first rater. Raters agreed on the presence and type of dementia in 153 relatives age 45 or […]

      Read More

      Premorbid sociosexual functioning and long-term outcome in schizophrenia

      by Brittany Scaturro | February 28, 1989 | Publications and Articles

      Chronic schizophrenic patients with the most severe social deterioration have been shown to differ from other chronic schizophrenic patients with respect to measures of left-to-right ventricular asymmetry, negative symptoms, and response to haloperidol treatment. In the current study, the authors investigated the social antecedents of these characteristics of very poor outcome schizophrenia in 69 chronic […]

      Read More

      Characteristics of very poor outcome schizophrenia

      by Brittany Scaturro | July 29, 1987 | Publications and Articles

      The authors compared 21 “Kraepelinian” schizophrenic patients who had been ill and dependent on others for the past 5 years with 76 chronic schizophrenic patients in remission or with exacerbations requiring hospitalization. The Kraepelinian patients met the criteria for schizophrenia by more diagnostic systems than the exacerbated patients, were less responsive to haloperidol, had more […]

      Read More

        • Sort By
        • All Resources
        • Presentation
        • Poster
        • Publications and Articles